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Scuola di Scienze
Corso di Laurea Magistrale in Fisica
A METHOD FOR AUTOMATED
GENERATION OF RADIOTHERAPY
TREATMENT PLANS FOR LUNG
CANCER
Relatore:
Dott. Nico Lanconelli
Correlatore:
Dott. Maarten L.P. Dirkx
Presentata da:
Giuseppe Della Gala
Sessione II
Anno Accademico 2014/2015
ii
Abstract
The fight against cancer is one of the main challenges in current medical science and
radiotherapy represents one of the most employed techniques, especially for tumors in
advanced stage. The radiation deposits energy in the tissues giving rise to reaction
processes in the molecules and in the structures they belong to, such as the DNA;
damages to the DNA sequence can lead the cell to death, with higher probability in
cancer cells.
Along the years, radiotherapy developed always more technically advanced techniques
for radiation delivery. Currently, intensity modulated radiotherapy (IMRT), based on
the addition of intensity modulated fields to deliver high dose to the target and spare the
healthy tissues, is overall the most employed delivery mode, while volumetric modulated
arc therapy (VMAT) is a relatively new delivery mode based on IMRT principles, in
which radiation is continuously delivered in an uninterrupted arc.
Independently of the delivery mode, radiotherapy treatment plan generation requires
a lot of human interaction and experience. A dosimetrist has the task to generate a plan
within a list of clinical requirements by selecting cost functions and their goals based on
previous experience only, while the treatment planning system looks for the best IMRT
segments arrangement. After the evaluation of a physician, the plan generation might
start again, in a trial-and-error process that is time consuming, with no guarantee about
optimality of the plan with respect to the wishes of the physician, and affected by the
dosimetrist’s experience and skills.
An alternative way is represented by automated treatment planning. The Era-
smus Medical Center Cancer Institute (Rotterdam, The Netherlands) in-house developed
Erasmus-iCycle is a multicriterial plan optimization algorithm for beam intensity opti-
mization based on a so called wish list. Outputs of iCycle, used in connection with a
treatment planning system, are Pareto-optimal plans with optimized intensity modula-
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ted beam profiles. With Pareto-optimal it is meant that none of the objectives in the
applied wish list can be improved any further without deteriorating higher prioritized
objectives. With automated planning, plan quality is more consistent, overall higher,
and plan generation is briefer in terms of hands-on working time by an operator.
In this study, an automated plan generation procedure was developed and evaluated
for non-small cell lung cancer at locally advanced stage. The selected delivery mode
was VMAT, that was not used in clinic yet at the time of the study for this site. A
site-specific iCycle wish list was generated in an iterative procedure on a small set of
previously treated patients with the help of two medical physicists and two radiation
oncologists. The procedure was then validated on a larger set of patients, previously
treated at the Erasmus Cancer Institute between January and August 2015.
In the vast majority of cases the automatically generated plans were judged by the
physicians as better than the corresponding clinically delivered, manually generated,
IMRT plans. Only in a few cases a brief patient specific manual fine tuning was reque-
sted to fulfill all the clinical constraints. For a small set of patient it was shown that
plan quality for automated VMAT plans was equal or superior with respect to VMAT
plans manually generated by an expert dosimetrist. For some patients the automated
procedure was able to generate plans with higher prescription dose with respect to the
clinically delivered one without violating any of the clinical constraints.
Overall, this study proved that an automated procedure was able to generate hi-
gh quality VMAT plans with minimal human interaction. The clinical introduction of
the automated VMAT planning procedure for non-small cell lung cancer treatment at
Erasmus Medical Center Cancer Institute has been started in October 2015.
La lotta al cancro è una delle sfide più importanti della medicina contemporanea e
la radioterapia rappresenta una delle tecniche di cura più utilizzate, in particolare per
tumori in stadio avanzato. La radiazione deposita energia nei tessuti, dando origine a
processi di reazione nelle molecole e nelle loro strutture di appartenenza, come il DNA;
danni alla sequenza genica del DNA possono condurre la cellula alla morte, con una
probabilità più elevata nelle cellule tumorali.
Nel corso degli anni, la radioterapia ha sviluppato tecniche sempre più sofisticate di
irradiazione. Attualmente, la intensity modulated radiotherapy (IMRT), basata sulla so-
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vrapposizione di campi ad intensità modulata per somministrare una dose elevata al target
e limitare la dose ai tessuti sani, è complessivamente la tecnica più impiegata, mentre la
volumetric modulated arc therapy (VMAT) è una modalità relativamente recente, basata
sui principi IMRT, in cui la radiazione è somministrata continuativamente lungo un arco
senza interruzioni.
A prescindere dalla tecnica di irradiazione, la generazione di piani di trattamen-
to radioterapici richiede una grande quantità di interazione umana ed esperienza. Un
dosimetrista ha il compito di generare un piano entro una lista di requisiti clinici sele-
zionando cost functions e loro obiettivi sulla base dell’esperienza precedente, mentre il
treatment planning system si occupa della ricerca della miglior disposizione dei segmenti
ad intensità modulata. Dopo il giudizio di un medico, può essere necessario ricominciare
la creazione del piano da capo, in un processo di tipo trial-and-error che risulta essere
molto dispendioso in termini di tempo, senza garanzie sulla ottimalità del piano rispetto
alle richieste mediche, e influenzato dall’esperienza e dalle capacità del dosimetrista.
Una via alternativa è rappresentata dalla generazione automatica di piani di tratta-
mento radioterapici. Erasmus-iCycle, software prodotto presso Erasmus Medical Center
Cancer Institute (Rotterdam, The Netherlands), è un algoritmo di ottimizzazione mul-
ticriteriale di piani radioterapici per ottimizzazione di intensità basato su una wish list.
L’output di iCycle, usato in congiunzione con un treatment planning system, consiste
di piani Pareto-ottimali con profili di radiazione ottimizzati ad intensità modulata. Con
Pareto-ottimale si intende che nessun obiettivo nella wish list selezionata può essere ul-
teriormente migliorato senza peggiorare il risultato ottenuto per un obiettivo a priorità
più elevata. Con la generazione automatica, la qualità del piano è più coerente e com-
plessivamente più elevata e la generazione del piano è più rapida in termini di tempo di
lavoro manuale da parte di un operatore.
Nel seguente studio, una procedura di generazione automatica di piani di trattamento
è stata sviluppata e valutata per carcinoma polmonare non a piccole cellule (non-small
cell lung cancer) in stadio localmente avanzato. La modalità di irradiazione scelta è
stata VMAT, non ancora impiegata nella pratica clinica per questo sito al momento
dello studio. Una wish list per iCycle specifica per il sito è stata generata attraverso
una procedura iterativa su un ristretto gruppo di pazienti trattati in precedenza con la
collaborazione di due fisici medici e due oncologi. La procedura è stata in seguito validata
su un gruppo più ampio di pazienti, trattati presso Erasmus Cancer Institute tra gennaio
v
ed agosto 2015.
Nella grande maggioranza dei casi, i piani generati attraverso la procedura auto-
matizzata sono stati giudicati dagli oncologi migliori rispetto ai rispettivi piani IMRT
somministrati in clinica e generati attraverso la procedura manuale standard. Solo in
pochi casi una rapida calibrazione manuale specifica per il paziente si è resa necessaria
per soddisfare tutti i requisiti clinici. Per un gruppo ristretto di pazienti si è mostrato
che la qualità dei piani VMAT automatici era uguale o superiore rispetto ai piani VMAT
generati manualmente da un dosimetrista esperto. Per alcuni pazienti la procedura auto-
matica è stata in grado di generare piani con una prescrizione di dose più elevata rispetto
a quella somministrata in clinica senza violare alcun vincolo clinico.
Complessivamente, questo studio ha dimostrato che è stato possibile generare piani
radioterapici VMAT ad alta qualità attraverso una procedura automatica con interazione
umana minima. L’introduzione clinica della procedura automatica per il trattamento
del carcinoma polmonare non a piccole cellule presso Erasmus Medical Center Cancer
Institute è iniziata nell’ottobre 2015.
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Chapter 1
Introduction
1.1 What is cancer
Cancer is the name given to a collection of related diseases (more than 100, generi-
cally classified by the type of cell that is initially affected) which involves abnormal cell
growth with the potential to spread into surrounding tissues. The peculiarity of spread-
ing distinguishes malignant tumors (the real cancer) and benign tumors. Cancer may be
caused by genetic and environmental factors.
The human body is made up of trillions of cells which normally grow and divide to
form new cells as the body needs them. When cells grow old or become damaged, they
die and new cells take their place. This process takes the name of apoptosis. In contrast
to necrosis, which is a form of traumatic cell death due to an acute cell injury, apoptosis
is a highly regulated and controlled process. It can be considered as a deliberate suicide
of the cell that takes place when it is needed by the whole system: self-sacrifice—as
opposed to survival of the fittest—is then the rule. Thus, to survive and divide without
limit, a prospective cancer cell must accumulate mutations that disable the normal safety
mechanisms that would otherwise induce a cell that is stressed, in this or in other ways,
to commit suicide. In fact, one of the most important properties of many types of cancer
cells is that they fail to undergo apoptosis when a normal cell would do so. Nevertheless,
this does not mean that cancer cells rarely die: on the contrary, in the interior of a large
solid tumor, cell death often occurs on a massive scale, because of the severe competition
among the cancer cells for oxygen and nutrients, but typically this happens much more by
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necrosis than by apoptosis. The whole tumor grows because the cell birth rate outpaces
the cell death rate, but often by only a small margin. For this reason, the time that a
tumor takes to double in size can be far longer than the cell-cycle time of the tumor cells
[1].
As previously outlined, cancer cells are also characterized by the ability of invading
and colonizing territories normally reserved for other cells. Invasiveness makes the dif-
ference between benign and malignant tumors. In particular, the formation of secondary
tumors, called metastases, is often the actual cause of the death of the patient.
1.1.1 Cancer stages
Staging is a classification of the tumors which describes the extent or spread of cancer
at the time of diagnosis (Fig. 1.1). Proper staging is essential in determining the choice
of therapy and in assessing prognosis. A cancer’s stage is essentially based on the size or
extent of the primary tumor and whether it has spread to nearby lymph nodes or other
areas of the body. Different staging systems are used to classify cancer. For instance,
a system is used for descriptive and statistical analysis of tumor registry data and is
particularly useful for looking at trends over time. According to this system, if cancer
cells are present only in the layer of cells where they developed and were not yet spread,
the disease is in situ. If cancer cells have penetrated beyond the original layer of tissue,
the cancer has become invasive and is categorized as local, regional, or distant, based on
the extent of spread.
Figure 1.1: Diagram of the progression of the cancer disease
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Clinicians use a different staging system, called TNM, for most cancers. The TNM
system assesses cancer growth and spread by three parameters: i) the size of the primary
tumor (T), (ii) the number of involved regional lymph nodes (N), (iii) the absence or
presence of distant metastases (M). Once the T, N, and M categories are determined,
a stage of 0, I, II, III, or IV is assigned, with stage 0 being in situ, stage I being early,
and so on, with stage IV being the most advanced disease [3]. A detailed description of
TNM staging is shown in Figure 1.2.
Figure 1.2: Detailed TNM staging of lung cancer (from [2])
1.2 Interactions between radiations and matter
Radiation can be classified in two main categories: ionizing and not ionizing radiation
(Fig. 1.3). This classification depends on the capability of the radiation to ionize matter.
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The ionizing process can also follow different ways. In particular, a remarkable distinction
between directly and indirectly ionizing particles can be made. In contrast to directly
ionizing particles (electrons, protons, ions), indirectly ionizing particles (photons and
neutrons) have no charge. As the name states, in this case ionization is a secondary
process of the interaction between the radiation and matter, generating fast charged
particles.
Radiotherapy takes advantage of ionizing radiation to kill cancer cells and treat the
tumor, by application of photons, electrons, protons, neutrons or ions. The interaction
between radiation and matter depends strongly on mass and charge of the radiation.
Figure 1.3: Classification of radiation
1.2.1 Photons
Depending on their origin, photon radiation generation falls into one of the following
categories[4]:
• Bremsstrahlung (continuous X-rays), generated through electron-nucleus interac-
tions
• Characteristic, discrete X-rays, emitted during transitions of orbital electrons from
one orbit to a vacancy in another inner orbit
• Gamma-rays (discrete), emitted through nuclear transition in gamma decay
• Annihilation radiation (discrete, 0.511 MeV), emitted through positron-electron
annihilation
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Photons may undergo various possible interactions with the atoms of a material. The
probability to manifest each interaction depends mainly on the energy of the photon and
on the atomic number Z of the attenuator. The energy of the interacting photon can
generate free fast charged particles (such as electrons) being entirely absorbed or may
undergo a process in which the outcome consists in a fast charged particle plus a scattered
photon. The generated charged particles gradually lose energy by transferring it to the
atoms of the material and by causing ionizations.
1.2.1.1 Photon beam spectrum
External beam radiation therapy is commonly based on X-ray photon beams as
bremsstrahlung radiation (electron - nucleus interaction) or characteristic X-rays (elec-
tron - electron interaction). This radiation is obtained by interaction of a high-energy
electron beam (typically 4-23 MeV) with a high-Z target (often tungsten, Z = 74) in the
head of the treatment machine. The resulting photon beam spectrum consists of contri-
butions of both processes: a continuum energy spectrum generated by bremsstrahlung
and discrete energy peaks caused by characteristic radiation of the target material.
If no filtration of the beam is applied, the energy spectrum will be a straight line and
mathematically given by Kramer’s equation:
IE = KZ(EMAX − E) (1.1)
where IE is the intensity of photons with energy E, Z is the atomic number of the target,
EMAX is the maximum photon energy, and K is a constant. The maximum possible
energy that a bremsstrahlung photon can have is equal to the energy of the incident
electron, which is generally between 4 and 25 MeV in radiation therapy. The addition of
a filter modifies the spectrum. The filtration primarily affects the low-energy part of the
spectrum and hardly affects the high-energy photon distribution. This process is known
as beam hardening and has the effect to increase the average energy of the beam by
absorbing lower-energy components of the spectrum, thereby improving the penetrating
power of the beam. In figure 1.4 the spectrum is shown for a X-ray tube.
Since X-rays have a spectral distribution in energies, it is difficult to characterize
the beam quality. In radiotherapy, beam quality is globally indicated by the maximum
photon energy in the spectrum, as determined by the energy of the electrons used to
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Figure 1.4: Spectral distributions of x-rays calculated for a thick tungsten target using
Kramer’s Equation (1.1). Dotted curves are for no filtration and solid curves are for a
filtration of 1 mm aluminum.
generate the X-rays. For instance, a beam with a maximum photon energy of 6 MeV
is called a 6MeV photons beam. A rule of thumb which is often used states that the
mean photon beam energy is approximately one third of the maximum energy, but this
one-third rule is a rough approximation since filtration may significantly alter the mean
energy[5].
1.2.1.2 Photoelectric effect
In the photoelectric effect, a photon interacts with a tightly bound orbital electron
of a material and disappears, while ejecting the orbital electron from the atom as a
photoelectron with a kinetic energy EK given as:
EK = hν − EB (1.2)
where hν is the incident photon energy and EB is the binding energy of the electron.
This process cannot occur with a free electron: the atom is needed in order to conserve
momentum[6].
In general, the cross section σpe for photoelectric absorption increases strongly with
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decreasing photon energy. The cross section displays a series of discontinuities at energies
corresponding to the binding energies of the electrons in the atomic shells, known as
absorption edges. Below the absorption edge, the photon does not have sufficient energy
to liberate an electron from the shell; at energies just above the edge, the photon has
sufficient energy to liberate the electron. Therefore, the cross section abruptly increases
because the number of electrons that can take part in the absorption process increases.
The cross section for photoelectric effect depends strongly on atomic number. Above
the K-shell absorption edge, the cross section per atom as a function of photon energy
and atomic number is approximately given by
σpe ∝ Z4/(hν)3. (1.3)
This points to the strong impact of this process at low photon energies and, particularly,
at high atomic numbers.
1.2.1.3 Coherent scattering
In coherent (or Rayleigh) scattering, a photon interacts with a bound orbital electron.
The event is elastic in the sense that the photon loses essentially none of its energy and
is scattered through a small angle only. Since no energy transfer occurs from the photon
to charged particles, Rayleigh scattering plays no role in the energy transfer coefficient,
but it contributes to the attenuation coefficient.
In tissue and tissue equivalent materials, the relative importance of Rayleigh scatter-
ing in comparison with other photon interaction processes is small, as it contributes a
few percent or less to the total attenuation coefficient only[4].
1.2.1.4 Incoherent scattering
The Compton effect (incoherent scattering) consists of a photon interaction with an
essentially ‘free and stationary’ orbital electron. The incident photon energy hν is much
larger than the binding energy of the orbital electron (hν  EB). The photon transfers
part of its energy to the recoil (Compton) electron and is scattered as photon hν ′ through
a scattering angle θ.
To satisfy the conservation of momentum and energy, the scattered photon is char-
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acterized by an energy
hν ′ =
hν
1 + hν
mec2
(1− cos θ)
(1.4)
where hν is the energy of the incident photon, me is the rest mass of the electron, and
θ represents the angle between the incident photon direction and the direction of the
scattered photon.
Compton scattering cross section is given by the Klein-Nishina equation, which shows
a linear dependence on the atomic number Z of the attenuator. In the usually applied
MeV energy photon beams, the Compton effect is the dominant interaction type.
1.2.1.5 Pair production
In pair production, a photon is absorbed in the electric field of the nucleus and
an electron-positron pair is created and emitted with a total kinetic energy equal to
hν − 2mec2, due to the conservation of energy. The process requires a minimum photon
energy (energy threshold) of 2mec
2 = 1.022 MeV , necessary to create the two particles.
On average, the electron-positron pair about equally shares the kinetic energy available.
This energy is then lost into the attenuator material.
The cross section for pair production in the nuclear field is zero below threshold and
rapidly increases with increasing energy for higher energies. Above threshold, it varies
approximately as the square of the nuclear charge Z, i.e.
σpp ∝ Z2. (1.5)
Regions of relative predominance of photoelectric, Compton and pair production
effects are shown in Figure 1.5.
1.2.1.6 Photon beam intensity attenuation
The intensity of a photon beam is defined as the flow rate of photon energy through a
unit area lying perpendicular to the beam direction. When a X-ray beam passes through
matter, the beam intensity is reduced due to attenuation by the medium. This process
involves absorption, scattering and transmission.
It is straightforward to demonstrate that the intensity I(x) of a narrow beam of
monoenergetic photons, attenuated by an absorber of variable thickness x, is given by
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Figure 1.5: Regions of relative predominance of the three main forms of photon interac-
tion with matter. The left curve represents the region where the atomic coefficients for
the photoelectric effect and the Compton effect are equal, the right curve is for the region
where the atomic Compton coefficient equals the atomic pair production coefficient.
the following equation:
I(x) = I0e
−µx (1.6)
where I0 is the intensity incident on the absorber and µ = µ(hν, Z) is the total linear
attenuation coefficient, which depends on the beam energy hν and the atomic number
Z of the attenuator.
The linear attenuation coefficient is the probability per unit length for interaction
and is related to the total atomic cross section σtot through the relation
µ = Nσtot (1.7)
where N is the number of target entities per unit volume, i.e.,
N =
NA
A
ρ (1.8)
NA is the Avogadro’s number (NA = 6.022× 1023 atoms/mol), A is the relative atomic
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mass of the target element and ρ is its density. It is also useful to define the mass
attenuation coefficient µm = µ/ρ , which can be considered as a more fundamental
coefficient than the linear coefficient, since its dependence on the nature of the material
does not involve density but rather the atomic composition. The total attenuation
coefficient is the sum of the coefficients for individual photon interactions.
In radiotherapy, beams energies typically vary between 4 and 23 MeV, so the pre-
dominant effect is the Compton scattering (Fig. 1.6).
Figure 1.6: The total and partial cross-sections for carbon (a) and lead (b) for photon
energies from 10 keV to 100 MeV
1.2.1.7 Dose delivery
When a photon beam enters the patient body, it interacts with its tissues by de-
positing energy following the previously described processes. The absorbed energy is
10
therefore not only deposited locally at the site where the photon has interacted, but also
at a further distance. This happens due to the creation of fast electrons or positrons
that will gradually lose energy while moving away from the photon interaction site.
These charged particles often have a large velocity component in the forward direction
and for this reason dose is mainly released forward, resulting in a low dose near the
surface, the so-called dose buildup region. High energy photons produce high-speed
electrons and the dose buildup region is then more significant. With depth, the photon
beam intensity reduces, resulting in less dose at larger depth.
The delivered dose as a function of depth in a medium varies depending on many
parameters, like beam energy, field size, and the distance from the source (Fig. 1.7. One
way of characterizing the central axis dose distribution is to normalize dose at a certain
depth with respect to dose at a specific reference depth. The percentage depth dose may
be defined as the quotient, expressed as a percentage, of the absorbed dose (indicated
here by the symbol D) at any depth d to the absorbed dose at a fixed reference depth
d0, along the central axis of the beam. Percentage depth dose (PDD) is thus:
PDD =
Dd
Dd0
× 100 (1.9)
For orthovoltage X-rays (up to 400 keV ), the reference depth is usually the surface
(d0 = 0); for higher energies, the reference depth is taken at the position of the peak
absorbed dose (typically 1.5 cm for a 6 MV beam and 3 cm for a 23 MV beam).
1.2.2 Charged particles
Charged particles are fundamental to the medical use of radiation. They may be
delivered as primary radiation beam, using electrons, protons or so called heavy ions
like carbon. Alternatively, if the primary radiation is a photon beam, charged particles,
known as secondary radiation, are causing the biological effect. Therefore, it is important
to obtain a model for the transport of energy by the charged particles.
1.2.2.1 Electrons
Electron beams of MeV energy are used for treatment of superficial tumors (i.e., less
than 5 cm in depth), e.g. in the skin, breast and head and neck area (Fig. 1.8). The
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Figure 1.7: Relative dose release for different photon energies. Field size 10 × 10 cm2;
source to surface distance (SSD) = 100 cm for all beams except for 3.0 mm Cu half-
value layer (250 kV) (SSD = 50 cm). It is possible to observe the dose build-up region,
clinically known as the skin sparing effect.
principal way that charged particles lose energy in the materials is by Coulomb interac-
tion in inelastic processes with the bound atomic electrons (ionizations and excitations)
and atomic nuclei (bremsstrahlung). The particle creates a trail of ionizations and ex-
citations along its path and through these processes the electron may lose its kinetic
energy or change its direction of travel (scattering).
• The rate of energy loss by collisional losses (ionization or excitation) depends on
the electron density of the medium and is greater for low atomic number Z. This
happens both because high Z materials have a low electron density and because
high Z materials have more tightly bound electrons, which are not available for
this type of interaction. The energy loss rate first decreases and then increases
with an increasing electron energy.
• The rate of energy loss by radiation losses (bremsstrahlung) is approximately pro-
portional to the electron energy and to the square of the atomic number Z. This
means that X-ray production is more efficient for higher energy electrons and ab-
sorbers with a higher atomic number.
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Figure 1.8: Typical central axis percentage depth-dose curves for beam energies from 5
MeV to 20 MeV
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1.2.2.2 Protons and ions
Protons are charged particles and are relatively heavy compared to electrons. The rest
mass of a proton is 1836 times the rest mass of an electron. Depending on their energy
(i.e., their velocity), they interact with the medium through mechanisms as inelastic or
elastic collision with the nucleus or with the bound atomic electrons.
Because of the strong electric force between protons and the atoms of a medium, these
particles can be stopped by matter with relative ease. Especially compared to photons,
protons release a great amount of energy in a shorter distance and they are stopped more
rapidly. As the beam traverses the tissue, the dose deposited is approximately constant
with depth until near the end of the range, where the dose peaks out to a high value
followed by a rapid fall off to zero. The region of high dose at the end of the particle
range is called the Bragg peak. Immediately after the Bragg peak, the proton beam
stops completely and does not deposit any dose (Fig. 1.9).
The characteristic dose distribution makes protons very suitable for tumor treatment.
If the selected proton energy has the Bragg peak corresponding to the tumor site, much
of the energy is deposited in the tumor itself and the adjacent organs at risk are relatively
spared. On the other hand, a very good dose calculation is needed to assure the tumor
being irradiated properly.
In clinical practice, the raw peak is too narrow for clinical applications. One solution
is to superimpose, during the irradiation, a certain number of peaks placed at various
depths with a modulator to ensure a homogeneous coverage of the target volume. The
resulting dose distribution takes the name of Spread Out Bragg Peak (SOBP, Fig. 1.10).
With this approach, the dose at the surface will be increased relative to the peak of the
SOBP and the skin dose could be higher than that caused by a high-energy photon beam,
representing one of the principal limitations of the use of proton beams for therapy.
Recently not only proton therapy has rapidly developed, but also therapy with heavy
ions (e.g., carbon ions) has gained attention. Compared to protons, carbon ions have
the advantage of a higher biological efficiency due to a higher density of ionization at the
end of their range. In other words, the Bragg peak in the dose distribution is even higher
and the dose fall off is even steeper compared to protons. On the other hand, heavy ions
have the disadvantage that beyond the Bragg peak the dose does not decrease to zero,
showing a tail in the depth dose distribution.
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A comparison between photons, electrons and protons percentage depth doses is
shown in Figure 1.11.
Figure 1.9: Percentage depth doses in water for proton beams at various energies
Figure 1.10: Comparison between the percentage depth doses of a spread out Bragg peak
(SOBP) and a single proton beam
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Figure 1.11: Relative dose as a function of the depth for different kinds of radiation
1.3 Biological mechanism of radiotherapy
1.3.1 Working principles
A beam of ionizing radiation that passes through biological matter gives rise to phe-
nomena of interactions with the atoms, as previously described. During these processes,
the radiation transfers a certain quantity of energy, typically higher than the binding en-
ergies of atoms and molecules, to the atoms. The energy transfer causes ionization and
excitation of the atoms, enhancing their chemical receptivity and giving rise to reaction
processes with consequent modifications of the structure of the molecules they belong
to. In particular, when water (which is the most prevalent molecule within the cell) is
irradiated, so called free radicals are created by radiolysis. Free radicals are highly un-
stable and react with other nearby molecules, therefore transferring chemical damage to
them. All components of the cell may be damaged in this way, such as proteins, enzymes
and so on, but a damage to most of them probably has little impact on the viability of
the cell. But one cellular component is almost unique: DNA. Radiation damage may
lead to modification of some of the genes that form the DNA and thus to loss of specific
functions (some of which may be essential for survival). For this reason DNA is the most
vulnerable part of a cell to radiation damage: even small changes in its composition may
cause the loss of the colony-forming ability of the cell. In order to prevent this, cells have
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very efficient repair processes, based on enzymes which are able to continually monitor
the integrity of the DNA, recognize damage and repair it[6]. The radiosensitivity of cells
varies considerably as they pass through the cell cycle. Cells are most sensitive during the
mitosis phase, part of the cell reproduction cycle. This is probably due to the fact that
at that moment cells have little time to repair radiation damage before being called upon
to divide. The main features of tumor cells that make radiotherapy a successful cancer
treatment are their faster speed to reproduce and their reduced ability to repair DNA
damage compared to most healthy tissue cells. Unrepaired DNA damages accumulate
in cells that reproduce, finally leading to cell death. The action of ionizing radiation on
biological structure can be divided in four stages: physical, physical-chemical, chemical
and biological stages, characterized by very different times.
• Physical stage: this is the first stage of the energy transfer to the biological sys-
tem. The interactions of the radiation with the atoms cause the ejection of one or
more atomic electrons, producing secondary ionizations due to subsequent chemi-
cal transformations. The ionization density that is generated along the path of the
charged particles is described by the Linear Energy Transfer (LET), defined as the
mean energy delivered by the primary and the secondary charged particles over a
distance of 1µm.
• Physical-chemical stage: the absorption of energy from ionizing radiation produces
damage to molecules by direct and indirect actions. Direct action involves the ion-
ization of atoms on key molecules that causes inactivation or functional alteration
of the molecule. Indirect action involves the production of reactive free radicals,
neutral atoms or molecules characterized by the presence of an unpaired electron in
the external orbit that causes a very high chemical receptivity. Direct effect is the
predominant cause of damage in reactions involving high LET radiation (i.e., alpha
particles, neutrons, protons and heavy ions) whereas indirect action is predominant
for low LET radiation, like photons.
• Chemical stage: during this stage reactions involving free radicals occur, provoking
the formation of molecules with abnormal structures.
• Biological stage: during the last stage, formation of injuries on all levels occurs.
This involves transformations in cell structures and functions and mutations of the
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chromosomal content of the cells that may prevent further cell reproduction and
lead to cell death.
1.3.2 Stochastic nature of energy deposition
The absorbed dose arises from the deposition of energy in matter by radiation tracks.
This is an inherently random process. Figure 1.12 shows the amount of energy E, being
deposited in ever decreasing volumes of mass m centred on the same point in an uniform
medium, for series of irradiations of identical duration[6]. For large volumes, E/m has
the same value each time; below a certain value of m, fluctuations start to appear which
increase as m decreases. Energy is deposited through interactions with particles along
the tracks. When the volume gets small enough, it may contain only few or even no
particles along the tracks, while others still contain many. Therefore, in the same fluence
condition, at some size of the elementary volume the randomness of energy deposition
will become apparent.
At large values of m E/m is not constant either. At that point, the path length
becomes comparable with the mean free path for radiation interactions. For this disser-
tation, this is not relevant.
Figure 1.12: Energy deposited per unit mass, plotted against the mass, m, of the scoring
volume, as this volume is gradually changed in size for a given incident radiation fluence.
The shaded portion represents the range where statistical fluctuations become important
as the volume (i.e., the mass) is getting smaller
18
1.3.3 Dosimetric units and parameter
The most important unit in radiation dosimetry is the absorbed dose D, defined as
D =
dε̄
dm
(1.10)
where dε̄ is the mean energy imparted by ionizing radiation to matter of mass dm. The
unit of absorbed dose is the Gray [Gy], or Joule per kilogram [J · kg−1].
The kerma (kinetic energy released to the matter), labelled with K, is the quotient
dEtr by dm, where dEtr is the sum of the initial kinetic energies of all the charged ionizing
particles liberated by uncharged ionizing particles in a material of mass dm:
K =
dEtr
dm
(1.11)
The unit of kerma is identical to the one for absorbed dose (Gy or J · kg−1). In contrast
to absorbed dose, kerma applies to indirectly ionizing radiation, like photons, only.
The equivalent dose H is a dose quantity to represent the probability of cancer in-
duction and genetic damage. It is based on the absorbed dose, but takes into account
the biological effectiveness of the radiation, which is dependent on the radiation type
and energy:
HT =
∑
R
WR ·DT,R (1.12)
T denotes a specific tissue, DT,R is the absorbed dose deposited in tissue T by radiation
type R and WR is the radiation weighting factor.
The effective dose E is the tissue-weighted sum of the equivalent doses in all specified
tissues and organs of the body and represents the stochastic health risk, which is the
probability of cancer induction and genetic effects of ionizing radiation delivered to the
body:
E =
∑
T
WT ·HT (1.13)
WT is the tissue weighting factor and HT is the equivalent dose delivered to tissue T .
To obtain the total effective dose, it is necessary to sum over all irradiated tissues. The
unit of effective dose is Sievert [Sv], which corresponds to 1 Joule per kilogram [J ·kg−1].
Although this unit is identical to the one of absorbed dose, its meaning is different.
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1.3.4 Cell survival curves
The aim of radiotherapy is to kill tumor cells by irradiation, while healthy tissue
cells should be able to withstand, at least at a percentage, in order to avoid compromise
in organ functionality. In order to quantify this, cell survival curves are introduced.
A cell survival curve shows the relation between the deposited dose (or a generic cell-
killing agent) and the fraction of surviving cells. When plotted on a linear scale, the
survival curve for cells irradiated in tissue culture is often sigmoid. In practice, cell
survival curves are generally plotted on a logarithmic scale, because this allows effects at
a very low survival levels to be shown and compared more easily, which is very important
because the cure of a tumor requires many orders of magnitude of cell kill.
The type of radiation (high or low Linear Energy Transfer, LET) plays a role in
defining the shape of the survival curve: for high LET radiation, the curve turns out to
be much steeper (Fig. 1.13). Other important factors which influence the cell’s radiosen-
sitivity are the phase of the cell cycle (as reported in section 1.3.1), its oxygenation level
and the fractionation of the delivered dose.
Figure 1.13: Typical cell survival curves for high LET (densely ionizing) radiation and
low LET (sparsely ionizing) radiation
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1.3.4.1 Oxygenation
The response of cells to ionizing radiation is strongly dependent upon oxygen. With
a higher level of oxygen, more free radical reactions will occur, leading to more DNA
damage. The impact is similar at all levels of the survival curve (Fig. 1.14).
Figure 1.14: Survival curves for cultured mammalian cells exposed to x-rays under oxic
or hypoxic conditions. The shown oxygen enhancement ratio (OER) represents the ratio
of the doses in hypoxia and in air needed to achieve the same biological effect
1.3.4.2 Fractionation
A basic schedule of a radiotherapy treatment consists of irradiating the tumor with
a given total dose D, divided in n fractions of a certain amount of dose d, that are
administered with a certain frequency in a specific period of time t. The response of the
treatment is strongly dependent on this schedule.
Fractionation guarantees a discrimination between tumor and normal tissue cells.
By delivering the total dose in n fractions, normal tissues may generally be spared to a
larger extent, because during the time between subsequent fractions repair of sublethal
damage is enabled. As previously described, normal tissue cells have a faster repair
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mechanism than tumor cells. Furthermore, fractionation increases the amount of damage
to the tumor because it allows re-oxygenation between fractions, due to revascularization
processes. The cell survival curve for tumoral and normal cells is shown in Figure 1.15
as a function of the number of fractions.
Figure 1.15: Surviving fraction of tumoral and normal cells as a function of the number
of fractions
Many schedule for fractionation have been proposed. Most frequently, radiotherapy
treatment schedules are based on a dose of 2 Gy per fraction, delivered once a day, except
during weekends. But also hyperfractionation (i.e., with a reduced dose per fraction and
increased numbers of fractions , generally delivered twice a day), hypofractionation (i.e.,
with a larger dose per fraction and a smaller number of fractions, delivered in a shorter
overall time) and accelerated fractionation (i.e., with a conventional dose per fraction,
but a reduced overall treatment time, e.g., by irradiation during weekends as well) have
been clinically applied, with different benefits and drawbacks. The choice of fractionation
schedule is often highly dependent on whether radiotherapy is used with curative intent or
to reduce complaints of the patients (i.e., palliative intent) and whether other modalities
(i.e., surgery or chemotherapy) are included in the radiotherapy treatment as well.
1.4 Radiotherapy workflow
In the generation of a radiotherapy treatment plan, many steps are involved. All
stages have to be properly analyzed and performed, in order to achieve the best feasible
solution. Any fault in one of the steps could compromise the success of the whole process.
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In Figure 1.16 the so called chain of radiotherapy is shown[6].
Figure 1.16: The chain of processes leading to conformal radiotherapy and illustrating
that the physical basis of radiotherapy depends on good performance at each state
1.4.1 Aim of radiotherapy
As mentioned before, the purpose of radiotherapy is to deliver sufficiently high dose
to the tumor while minimizing damage to surrounding healthy tissues. It is usual to talk
about optimizing the so-called therapeutic ratio, i.e., finding the best balance between
trying to ensure that all tumor cells receive a lethal dose of radiation and that acute
and late effects in normal tissues are tolerable. To evaluate the therapeutic ratio, gen-
erally the tumor control probability (TCP) and normal tissue complication probability
(NTCP) are used. TCP and NTCP are mathematical models, describing the probabil-
ity of complete tumor eradication and any complication resulting from the radiotherapy
treatment, respectively. Both concepts are referring to probability, because the sensitiv-
ity to ionizing radiation is different from one person to another. TCP and NTCP are
sigmoid curves (Fig. 1.17) and the aim is to deliver a dose distribution that results in a
TCP close to 1, while NTCP remains at a low value. It is important to keep in mind that
any changes to the treatment regimen (e.g., fractionation, concurrent chemotherapy, and
so on) affect the therapeutic ratio and have to be properly evaluated.
In general, the radiotherapy intent can be curative or palliative. In the first case,
the objective is the destruction of all clonogenic tumor cells (i.e., cells characterized by
the ability of colony forming). For this aim, radiotherapy is often combined with other
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Figure 1.17: TCP and NTCP curves
treatments such as chemotherapy and surgery. In palliative treatment the aim is to reduce
or eliminate eventual symptoms of the disease such as pain, bleeding and compression
given by the tumor mass expansion. This kind of treatment is applicable when a definitive
treatment is not possible (e.g., because tumor cells were spread throughout the body),
mainly aiming at an improvement of the patient’s quality of life.
1.4.2 Positioning
An important issue in the radiotherapy process is the ability to reproduce accurately
the same patient position throughout the treatment and to keep the patient still during
each fraction. This fixed position must be decided upon before acquisition of the 3D
image set of the patient (cf. 1.4.3). The option to use optimal beam directions for
treatment without risk of collision with the treatment machine or accessories should
carefully be considered. Positioning accessories or immobilization devices (for instance
thermoplastic casts) are often used to achieve a high accuracy and reproducibility in
patient position during each treatment session. Before acquisition of the imaging data,
tattoos or other skin marks are often placed as a reference for patient positioning, to be
used in combination with the projection of lasers in the treatment room, coinciding at
the treatment isocenter.
In lung cancer treatment, patients are generally positioned supine with their arms
immobilized above their head in a comfortable arm support. The patient holds on to
a T-bar device with their elbows supported laterally. A knee support enables a more
comfortable, and therefore reproducible, set-up (Fig. 1.18).
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Figure 1.18: Immobilization for thoracic radiotherapy with a T-bar, lateral elbow sup-
ports and a knee rest. Laser lights are used to prevent rotational set-up errors. Picture
from [9].
1.4.3 Imaging
Once the patient positioning is defined, it is important to get 3D image information
of the patient, which is required to define the exact shape, position and electron density
of the tumor and the organs at risk. The ideal imaging modality should be well-tolerated
and atraumatic for the patient, quick (in order to minimize adverse effects of movements),
and should have a high resolution and a good contrast between different soft tissues, lungs
and bones.
For radiotherapy, the default image acquisition technique is Computed Tomography
(CT). CT is able to give anatomical information about the patient by measuring the ab-
sorption of X-rays photon beams from a continuous rotation. For CT generally photons of
about 100 keV are used. As previously discussed (cf. 1.2.1), for this energy the Compton
effect is the dominant interaction process, showing an attenuation that varies propor-
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tionally to the electron densities of the tissues and obtaining a spatial distribution of the
tissues absorption coefficients. As described in section 1.2.1.6, thickness is the feature
that mainly influences absorption, but, for equivalent thicknesses, the more the attenu-
ation, the higher the electron density. Besides CT scans, other imaging techniques such
as the Magnetic Resonance Imaging (MRI) or Positron Emission Tomography (PET) are
used as aid for volume definition. Some of these scans may give additional information
about the metabolic processes in the cells, enabling the identification of tumor masses
that are characterized by high reproducibility rate or which are well oxygenated. Espe-
cially a MRI scan often has a better contrast than a CT scan. Nevertheless, a CT scan is
still routinely used for treatment planning because, in contrast to MRI and PET images,
the pixel values (expressed in Hounsfield units) are proportional to electron densities,
which are required for an accurate dose calculation.
1.4.4 Volumes definitions
Once that the image acquisition is completed, the next step consists of delineation of
the tumor and normal tissues volumes. This task is mainly performed by a physician or a
trained dosimetrist following specific protocols (International Commission on Radiation
Units (ICRU) published recommendations Report 50 [1993], 62 [1999] and 83 [2010]).
After completion, a structure set containing at least the following volumes is defined:
• Organs at Risk (OARs): these structures are critical normal tissues whose radiation
sensitivity may significantly influence treatment planning and/or prescribed dose.
In some cases, it is necessary to add a margin which is able to take into account
uncertainties in daily patient positioning and/or changes in position and shape of
those organs during treatment delivery, yielding a Planning Organ at Risk Volume
(PRV). In lung cancer treatment, the main OARs to be considered are the healthy
lung tissues, spinal cord, esophagus, heart and plexus.
• Gross Tumor Volume (GTV): this volume corresponds to the primary tumor vol-
ume. In some cases, it can be useful or necessary to support the anatomical imaging
technique (i.e., CT) with a functional one (like PET). GTV always contains the
highest tumor cell density and is absent after complete surgical resection.
• Clinical Target Volume (CTV): CTV contains the GTV and subclinical microscopic
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disease that has to be eradicated to cure the tumor. Generally, subclinical disease
is too small to be identified as tumor cells in 3D imaging, but from literature it is
known to what regions cells from the GTV may expand. The margin between GTV
and CTV is derived by many aspects, such as histological examination, biological
characteristics of the tumor, local recurrence patterns and the experience of the
radiation oncologist. Variation in CTV delineation by the clinician is the greatest
geometrical uncertainty in the whole treatment process.
• Planning Target Volume (PTV): due to changes in patient positioning and/or in
position and size of specific organs, both during a treatment fraction and in between
fractions, the position of the CTV may also change. Therefore, in order to ensure a
homogeneous dose delivery to the whole CTV throughout a fractionated treatment,
an additional margin is generally added around the CTV itself. This margin has to
take into account physiological organ motions (internal margin, which identifies the
Internal Target Volume, or ITV) and possible variations in patient positioning and
beam alignments (set-up margin). Internal margin has to contemplate organ and
tumor motion. Variations in organ motion may be small (e.g., in the brain), larger
and predictable (e.g. respiration or cardiac pulsation), or unpredictable (e.g., due
to rectal and bladder filling). In lung cancer treatment, CTV-PTV margin has to
take into account all possible positions of the CTV during a respiratory cycle. To
reduce this safety margin, it can be useful to suspend patient respiration with a
technique such as the active breathing control (ABC) device. During a fractionated
course of radiotherapy, variations in patient position and in alignment of beams will
occur both during and in between treatment fractions. To take this into account,
a margin for set-up errors is incorporated in the CTV-PTV margin as well. Errors
may be systematic or random.
A schematic representation of the volumes defined by ICRU reports is shown in Figure
1.19. The target volumes delineation for a lung cancer patient is shown in Figure 1.20.
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Figure 1.19: Schematic representation of the volumes defined by ICRU reports
Figure 1.20: Target volumes delineation in a lung cancer patient
1.4.5 Forward and inverse planning
Plan generation can be performed following two different strategies. In forward plan-
ning, the dosimetrist places beams in a treatment planning system by choosing the
number of beams, beam orientations and weights. Generally each beam is shaped ac-
cording to the projection of the PTV. This technique has been used for years, but has
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little possibilities to tightly shape the high dose volume around the PTV and minimize
the dose in organs at risk. To improve plan quality, more sophisticated delivery tech-
niques, like Intensity Modulated Radiation Therapy (IMRT) and Volumetric Modulated
Arc Therapy (VMAT) have recently become available (cf. 1.5.2.2 and 1.5.2.3). It is
hardly possible to plan those techniques with a forward, manual technique, so in the
majority of cases an inverse planning technique is applied, in which the computer tries
to get a treatment plan that best satisfies the prescription of the user. So, this planning
strategy requires specification of the dose to be delivered in the GTV, CTV, PTV and
OARs, in terms of various constraints.
But also inverse planning generally involves a trial-and-error process. It is not
straightforward to define planning constraints that are realistic (but sufficient challeng-
ing) for a specific patient, so often several attempts will be required to get an acceptable
plan (Fig. 1.21). This means that for treatment planning still quite some time is re-
quired. Furthermore in the end it is still very difficult to assess whether the quality of
the obtained plans can still be improved. This makes that the final plan quality is partly
determined by the dosimetrist’s experience and by the available time to generate the
plan.
1.4.6 Evaluation
Before the delivery, the treatment plan requires a careful evaluation by a radiation
oncologist who has the task to assess whether the derived plan is adequate for treatment.
The plan has to fulfill a list of clinical requests relating to a proper coverage of the tumor
by the high dose region and a satisfactory sparing of OARs. This clinical list is strongly
related to the treatment modality (such as prescribed dose, fractionation and so on); an
example for lung cancer treatment can be found in section 3.2.2.
Many factors contribute to a proper evaluation of a radiotherapy treatment plan.
Some of them are strictly quantitative, while others can be more patient-specific: for
instance, for patients with a very low pulmonary function, more strict criteria on healthy
lung sparing may be required, even at the cost of worse target coverage.
• Dose Volume Histograms (DVH) are used to condense and display the 3D dose
delivery to an organ in a graph. A differential DVH shows the summed volume of
elements receiving dose in a specified dose interval, against dose. Generally, it is
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Figure 1.21: Diagram of the trial-and-error process involved in manual planning
more common to use cumulative dose volume histograms in which the total volume
receiving a dose greater than, or equal to, a given dose is plotted against dose.
Usually volumes are expressed as a percentage of the total volume. It is important
to realize that in a DVH positional information is lost (e.g., it is unknown in which
part of the volume the highest dose is delivered). Therefore, the display of DVHs
and the delivered dose in each of the CT slices are usually used in conjunction
with each other during treatment plan evaluation. For the PTV, the DVH should
show a uniform high dose delivery in the volume; i.e., preferably, the shape should
be a step function around the prescribed dose. DVHs for organs at risk should
preferably have a concave appearance: it may be generically acceptable either to
deliver a relatively high dose to a small volume or a low dose to a large volume.
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Through the use of DVHs it is straightforward to define dose volume reference
points: these parameters are points on the DVH curve and are usually expressed
as VDref , where Dref represents a dose expressed in Gy or a percentage of the
prescribed dose. For instance, V5Gy indicates the percentage of the total volume
which receives a dose greater than, or equal to, 5 Gy, while V95 is the percentage of
the total volume receiving a dose greater than, or equal to, 95% of the prescribed
dose. It is sometimes useful also to define reference points as DVref which indicates
the dose delivered to a volume equal to or greater than Vref (expressed as percentage
of the total volume of the structure). In addition, it is straightforward to evaluate
whether the dose in an OAR does not exceed a specified maximum tolerable dose
level (e.g., 50 Gy for the spinal cord). A typical example of cumulative DVH for
lung cancer is shown in Fig. 1.22.
• Conformity Index (CI): conformity is an important feature of a treatment plan
which can be used to evaluate to which extent the high dose volume is limited (i.e.,
conformed) to the tumor shape. A conformal plan does not present hot spots, i.e.
points with a high dose, far from the border of the target. Many conformity indexes
have been introduced; the most common is defined as the ratio between the absolute
V95 in the whole patient and the volume of the PTV. If CI = 1 and the high dose
is only in the PTV the conformity is optimum; CI < 1 indicates an underdosage
in parts of the PTV; CI > 1 shows that the high dose volume is extending outside
the PTV, causing potential damage to healthy tissues. More refined conformity
indexes able to consider the location of the high dose were introduced.
• Homogeneity Index (HI): the homogeneity index is intended to represent the level
of homogeneity of the dose delivered to the target. It is defined as
HI = (D2% −D98%)/D50% (1.14)
In the ideal situation, HI = 0.
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Figure 1.22: Example of Dose Volume Histogram for a lung cancer patient
1.4.7 After radiotherapy treatment: follow up and complica-
tions
During the months after the radiotherapy treatment, patients are regularly checked
by the physician to evaluate the tumor response to the treatment and to take care of
possible side effects. Complications are strongly connected to treatment modality and
involved sites; most common mid-term side effects are related to skin (such as, very
dry skin, darker appearance or different feeling to touch), hair (different hair color or
texture in the treated area, hair loss), development of red spidery marks on your skin
(telangiectasia) caused by small broken blood vessels, and loss of tissues elasticity. For
lung cancer treatment the most relevant side effect is pneumonitis, which appears three
to six months after irradiation.
Follow-up cancer care involves regular medical checkups that include a review of a
patient’s medical history and a physical exam. Follow-up care may include imaging
procedures, endoscopy, blood work, and other lab tests. Follow-up care is important
because it helps to identify changes in health. The purpose of follow-up care is to check
for recurrence (the return of cancer in the primary site) or metastasis. Follow-up care
visits are also important to help in the prevention or early detection of other types of
cancer, to address ongoing problems due to cancer or its treatment, and check for physical
and psychosocial effects that may develop months to years after treatment ends[8].
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1.5 External beam radiotherapy: radiation delivery
In external beam radiotherapy (EBRT) beams of ionizing radiation are produced
outside the patient and directed towards the tumor.
1.5.1 Photon beam production
Photon beams are generated by a linear accelerator (linac, Fig. 1.23(a) and 1.23(b)).
An electron gun is the source of electrons that are to be accelerated. The electrons are ob-
tained from a heated cathode by the process of thermoionic emission and are accelerated
by interaction with an electromagnetic field. The electrons are then focused onto a high-
atomic-number target (often tungsten), where they lose their energy by bremsstrahlung
radiation. At megavoltage energies, the principal directions of bremsstrahlung emission
is the forward direction, so it is often necessary to bend the electron beam before the
target is reached. The obtained X-ray beam, which is generically characterized by a
maximum extension of about 40× 40 cm2, is then collimated by a multi-leaf collimator
(MLC) which enables modelling the beam with various shapes (Fig. 1.23(c)). The MLC
has up to 80 pairs of leaves that can move independently, allowing any beam shape to
be produced subject to the width of the leaves (generally 0.5− 1 cm).
The challenge for accelerator design is to produce a stable (nearly) monoenergetic high
current electron beam concentrated onto a small focal spot, ensuring the production of
a sharply focused X-ray beam.
1.5.2 Main delivery modalities
1.5.2.1 3D Conformal Radiation Therapy (3DCRT)
Treatments are based on a 3D CT scan and a 3D delineation of the tumor and OARs.
Beam profiles are flat (i.e., uniform intensity over the field) or rather simply shaped by
a standard wedge.
1.5.2.2 Intensity Modulated Radiation Therapy (IMRT) - Step and shoot
IMRT is frequently used in EBRT. IMRT allows a better control of the delivered dose,
by varying the intensity within the treatment beam (fig. 1.25). Thanks to the use of
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Figure 1.23: Operating scheme of a linac and MLC
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the MLC, each treatment field can easily be divided in different subfields, characterized
by a different shape, position and intensity. Compared to 3DCRT, this allows to better
shape the dose delivery and to obtain a dose distribution which turns out to be more
conformal to the target volume and with a steeper dose fall-off towards organs at risk.
This is very important when treating tumors very close to sensitive organs at risk.
IMRT is usually delivered in step-and-shoot modality. A certain number of beam
orientations, typically between five and nine for lung cancer patients, are selected by the
dosimetrist. The treatment beam is switched off while changing from one subfield to the
other and while changing to the next treatment beam (i.e., no dose is delivered while the
MLC or gantry is moving). Due to the very large number of optimization parameters in
IMRT, inverse planning is generally used for treatment planning (cf. 1.4.5).
A comparison between 3DCRT and IMRT dose distributions for cancer treatment in
the pelvic region is shown in Figure 1.24.
Figure 1.24: Comparison between 3DCRT (left) and IMRT (right) dose distributions for
cancer treatment in the pelvic region. The figure shows how intensity modulation of
the beams affects the shaping of the high dose regions. Reported by Ekambaran et al.,
2014[10].
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Figure 1.25: Intensity modulation by superposition of MLC shaped fields from the same
directions. Vertical gray bars symbolize the tungsten leaves, white area in the centers
symbolizes the exposed area of the field. On the right, total intensity levels are symbol-
ized by gray values. White = high total intensity, dark = low intensity
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1.5.2.3 Volumetric Modulated Arc Therapy (VMAT)
As an alternative for IMRT, VMAT is often used. With VMAT radiation beams
sweep in uninterrupted arc(s) around the patient (Fig. 1.26), thereby allowing the de-
livery of a very conformal treatment plan in a shorter delivery time than with IMRT
(about 8 minutes instead of 20 minutes for lung cancer treatments). VMAT employs a
dynamic generation of intensity modulated fields: this means that the leaves of the MLC
move continuously during the dose delivery, allowing an infinite number of subfields. A
disadvantage of VMAT might be that in general a larger volume is treated to a low dose.
But for most tumor sites, this seems to be irrelevant. Due to the higher complexity level,
the optimization and calculation of the final dose distribution often takes longer than for
the other techniques, making a trial-and-error procedure even more time-consuming.
Figure 1.26: VMAT treatment
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1.5.2.4 Stereotactic radiotherapy and Cyber Knife
Stereotactic radiotherapy is a specialized high precision type of external beam radia-
tion therapy. Many non-coplanar photon beams are used to deliver a prescribed dose in a
very localized lesion with a very steep dose fall-off. The Elekta CyberKnife is a machine
developed for stereotactic treatment with a linac mounted on an industrial robotic arm
(Fig. 1.27). The CyberKnife is able to deliver photon beams from a lot of different
and even non-coplanar directions, yielding an increased degree of freedom for generating
optimal dose distributions.
Figure 1.27: CyberKnife radiosurgery system
1.6 Other cancer treatment modality:
brachytherapy and chemotherapy
1.6.1 Brachytherapy
The word brachy originates from the Greek word for short. So, brachytherapy can
roughly be translated as short-distance therapy. A radioactive material is inserted di-
rectly into or next to a tumor and concentrates the dose there, with a rapid fall-off. This
delivery mode has many physical and biological advantages because it makes possible
to deliver a high dose to the tumor and a substantially lower dose to the surrounding
tissue, due to the inverse square law that regulates the dose fall-off. The disadvantages
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of brachytherapy are that an operative procedure is often needed to access the tumor,
skilled personnel is required, and specific radiation protection measures has to be taken
to protect patient, staff and general public. Moreover, brachytherapy can only be used
for relatively small tumors. Brachytherapy is considered whenever possible for accessible
localized, small tumors. It is contraindicated when the tumor infiltrates bone, when the
margins of the tumor or target volume cannot be clearly identified and when there is an
active infection in the tissues.
The application of so-called “seeds” (Fig. 1.28) can be temporary or permanent and
the decision is taken by evaluating many aspects, such as the type of source, the shape
of the tumor and the possibility to reach an optimal source localization. Alternatively, a
source of low-energy gamma photons (e.g., iridium) can be inserted in or near the target
through a set of inserted needles.
Figure 1.28: Seeds for brachytherapy
1.6.2 Chemotherapy
Chemotherapy is a cancer treatment based on chemical drugs. It is often applied
when there is a high risk that tumor cells may be spread to other parts of the body.
The intent can be curative or palliative. Chemotherapy is often adopted as part of
a wider therapy which can also involve radiotherapy. In this case it is used to talk
about concurrent chemotherapy, when the therapy is administered contemporarily to the
radiation delivery, and sequential chemotherapy, when one therapy follows the conclusion
of the other. Chemotherapy plays an important role in the selection of the treatment
regimen.
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Chapter 2
Lung cancer and treatment planning
2.1 Lung anatomy and lung cancer features
The lungs are a pair of spongy, air-filled organs located on either side of the chest (tho-
rax). The trachea (windpipe) conducts inhaled air into the lungs through the bronchi,
which then divide into smaller and smaller branches (bronchioles), finally becoming mi-
croscopic. The bronchioles eventually end in clusters of microscopic air sacs called alveoli.
In the alveoli, oxygen from the air is absorbed into the blood. Carbon dioxide, a waste
product of metabolism, travels from the blood to the alveoli, where it can be exhaled.
Between the alveoli there is a thin layer of cells called the interstitium, which contains
blood vessels and cells that help support the alveoli. The lungs are covered by a thin
tissue layer called the pleura. The same kind of thin tissue, lining the inside of the chest
cavity, is also called pleura. A thin layer of fluid acts as a lubricant allowing the lungs
to slip smoothly as they expand and contract with each breath[11] (Fig. 2.1).
There are two major types of lung cancer:
• Small cell lung cancer (SCLC)
• Non-small cells lung cancer (NSCLC)
The name small cell lung cancer originates from the fact that under the microscope the
cancer cells look small and are mostly filled with the nucleus. SCLC occurs in about
15% of the total lung cancer patients. It often starts in the bronchi near the center of
the chest and tends to grow and spread quickly. In most cases it has already spread to
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Figure 2.1: Anatomy of the lungs (picture from [11])
distant parts of the body before the patient experiences complaints and the tumor is
detected. About 85% of lung cancer cases are classified as NSCLC. A combination of
small and non-small cell lung cancer is very uncommon. For NSCLC three main subtypes
can be distinguished: squamous cell carcinoma (25-30% of the total), adeno carcinoma
(40%) and large cell undifferentiated carcinoma (10-15%). These subtypes are identified
by different sites of origin, cells appearance, and behavior [12].
2.2 Lung cancer treatment options
2.2.1 Surgery
Surgical removal of the gross tumor, often in combination with other treatments, is
in general an option for early stage NSCLC and it often provides the best chance to
healing. In advanced stage (i.e., III and IV) NSCLC, surgery is frequently not feasible
due to the size of the tumor or to its spread to close lymph nodes. Different operations
can be used requiring general anesthesia [13]:
• Pneumonectomy: the entire lung that contains the tumor is removed
42
• Lobectomy: an entire lobe (i.e., anatomically and functionally independent struc-
tures in which the lungs are divided) is removed
• Segmentectomy: part of a lobe is remove
2.2.2 Chemotherapy
Chemotherapy drugs can be injected into veins or taken by mouth and similar treat-
ments can be useful for cancer in any part of the body. The therapy can be applied at
different stages of the whole treatment: before surgery, to shrink the tumor (neoadjuvant
therapy); after surgery, to try to kill the cancer cells that may have been left behind (ad-
juvant therapy); as main treatment, in combination with radiation therapy, especially
for advanced stage NSCLC. This can happen either concurrently to the radiotherapy or
sequentially (cf. 1.6.2). Chemotherapy is given in cycles (usually 1 to 3 days) followed by
a rest period to allow the body time to recover. An entire chemotherapy cycle generally
lasts about 3 to 4 weeks (4 to 6 for advanced stage)[14].
2.2.3 Radiotherapy
Radiotherapy is the main treatment option for advanced stage NSCLC. At Erasmus
Medical Center Cancer Institute, the clinical procedure involves IMRT (cf. 1.5.2.2) with
the number of beams varying from 5 and 9. The dose delivery usually takes up to 20
minutes.
2.2.3.1 4DCT Acquisition
The image acquisition is made with a 4DCT, i.e. many 3DCT scans (cf. 1.4.3) at
multiple phases of the breathing cycle where each image is tagged with breathing signals,
so that images can be sorted to the corresponding breathing phase. At Erasmus MC the
4DCT is acquired in free breathing condition [15].
2.2.3.2 Structures delineation
The GTV, CTV and organs at risks are delineated manually slice by slice on the 50%
exhale phase of the 4DCT scan (cf. 1.4.4) by expert dosimetrists under supervision of
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an oncologist physician. The PTV is generated by expanding the CTV automatically
with a 3D margin. The margin depends among other on the breathing amplitude of the
tumor, as determined on the 4DCT scan. The operators can be helped by the use of
software that can reconstruct intermediate slices by connecting manual delineations few
slices distant when the organs shape is smooth enough.
2.2.3.3 Dose prescriptions and fractionation regimens
The full prescribed dose for NSCLC treatment is 66 Gy. The dose can be mainly
delivered in two fractionation regimens: 33 fractions (i.e., 2 Gy per fraction) and 24 frac-
tions (i.e., 2.75 Gy per fraction). The first regimen is prescribed for patients subject to
concurrent chemotherapy, the second for patients who will receive sequential chemother-
apy (cf. 1.6.2). This prescription dose cannot always be achieved during the planning
phase without violating one or more clinical constraints (cf. 3.2.2). In these cases, the
number of fractions is reduced to 30 (i.e., 60 Gy) or 22 (i.e., 60.5 Gy) or less, without
considering the intermediate dose reduction due to limitation in the available time for
planning.
When the prescribed dose is not achievable even after the first dose reduction or
in presence of specific reasons (such as strict limitations in the overall therapy cycle
interval), a lower dose can be prescribed, typically 45 Gy. For this prescription dose, the 3
Gy per fraction regimen is adopted (cf. 3.2.6). As shown in the clinical requirements table
(Table 3.1), minor adjustments to the requirements are applied for different fractionation
regimens.
2.2.3.4 Delivery modalities
For many years lung cancer patients have been treated with 2D or 3D conformal
radiotherapy treatment techniques (cf. 1.5.2.1). With those techniques, the possibility
to escalate the target dose while not exceeding the dose tolerances for organs at risk
(such as healthy lung tissue) was limited. With the introduction of intensity-modulated
radiotherapy (IMRT, cf. 1.5.2.2) the dose to organs at risk could be reduced due to
a better shaping of the high dose region around the target volume and steeper dose
gradients outside ([16], [17]).
In recent years volumetric modulated arc therapy (VMAT, cf. 1.5.2.3) is increas-
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ingly used because of its improved delivery efficiency over fixed-field IMRT. The shorter
treatment time of VMAT may increase patient throughput, reduce the risk of intrafrac-
tion motion, and improve patient comfort during treatment [18]. For lung cancer stage
III/IV treatment, this is mirrored by a treatment time reduction from at about 20 min-
utes (IMRT) to at around 8 minutes (VMAT).
2.3 Introduction to treatment planning
2.3.1 Manual and automated planning
In the vast majority of radiotherapy departments generation of a treatment plan
requires a lot of human interaction and experience. After the delineation of the target
volume and organs at risk, a dosimetrist has the task to generate the best plan he/she
is able to achieve within the clinical constraints and requirements. This also applies for
generation of an IMRT or VMAT plan (cf. 1.5.2.2 and 1.5.2.3) using inverse planning
(cf. 1.4.5). The operator still has to select the beam orientations and has to define
specific constraints or objectives and weights for the target volume and organs at risk.
Also their goals have to be selected blindly, i.e., based on the dosimetrist’s experience
only. Then the treatment planning system looks for the IMRT segments arrangement
that minimizes an objective that is the weighted sum of different cost functions. The
different objectives are balanced without any information about relative importance or
priority. After optimization, the user evaluates the derived dose distribution. If the plan
is unsatisfactory, the process starts again with the definition of different constraints,
objectives and/or goals. This indicates that generation of an IMRT or VMAT plan is a
trial-and-error process. Due to this nature, the process is characterized by at least three
remarkable drawbacks:
• The process is time-consuming: the generation of a single final treatment plan
may take up to an entire day of work and, sometimes, the improvement is stopped
because no more time is available for the planner.
• The process is heuristic: it usually ends with a treatment plan for which, even if
it achieves all the clinical requirements, there is no guarantee that it best reflects
the wishes of the radiation oncologist.
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• The treatment plan quality is affected by the dosimetrist’s experience and ability
and by the complexity of the case.
Since these features are inherently tied to a manual planning procedure, an alternative
and extremely promising way is represented by automated planning. The Erasmus MC
in-house developed Erasmus-iCycle is a multicriterial plan optimization algorithm for
integrated beam angle and beam intensity optimization. Outputs of iCycle are Pareto-
optimal plans with optimized beam setup or optimized beam profiles. With Pareto-
optimal it is meant that none of the objectives in the applied “wish list” can be improved
any further without deteriorating higher prioritized objectives[19]. For more details on
iCycle working principles see 3.1.1. The main point here is that the use of iCycle allows
to obtain treatment plans with the following features:
• Plan quality is more consistent and not operator-dependent.
• The time necessary for plan generation is predictable and briefer than manual
planning.
• The overall quality increases and it is made sure to achieve an actual optimal
solution.
• Since the plan generation time is strongly reduced and the whole process does not
need any operator interaction, it is easier to investigate dose escalation (i.e., to
test whether it is possible to deliver a higher dose to the target without exceeding
the clinical constraints to the organs at risk) or intermediate dose reduction (cf.
2.2.3.3).
2.3.2 Background: research in radiotherapy treatment plan-
ning
Radiotherapy plan generation is a very lively field of study and research. During
the last years intense research all over the world was able to change the face of this
discipline and to achieve great improvements. In the next lines, a brief introduction to
contemporary issues about radiotherapy treatment planning is proposed to the reader.
For IMRT and VMAT it is still common practice that dosimetrists have to select the
optimization parameters manually in the previously described trial-and-error process. To
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tackle the drawbacks of this planning strategy, currently different automated planning
optimization procedures are being developed ([20], [21], [22]), aiming to achieve a high
quality treatment plan for any patient, independently of the dosimetrist’s skills. In
addition, the required hands-on working time for plan generation may significantly be
reduced.
Tol et al [22] designed an automatic interactive optimization procedure for VMAT
plan optimization based on dose-volume constraints and dose-volume histograms analyses
(DVHs, cf. 1.4.6). This method requires that the user knows the input priorities that
generally result in acceptable treatment plans for the majority of patients. But, with this
method, optimal plan quality for individual patients may not be guaranteed. In addition,
DVHs do not provide spatial information, such as the locations of the high- and low-dose
regions (“hot” and “cold” spots) inside the volume of interest[23]: small high-dose regions
may be unavoidable very close to the target volume but unacceptable far from the tumor.
Zhang et al [20] showed a completely automated process based on an in-house developed
optimization algorithm which employed a beam angle optimization process by using
a library of treatment plans delivered to previously treated patients. They compared
VMAT and IMRT planning techniques, and showed that the automatically generated
plans were generally preferred by oncologists when compared to manually generated
plans [18]. Their method did not apply a multi criteria optimization technique, but they
stated that it would be interesting to assess its additional value.
2.3.3 Erasmus-iCycle
At the Erasmus Medical Center Cancer Institute (Rotterdam, The Netherlands), a
fully automated and multi-criterial planning procedure was developed. In combination
with a treatment planning system, iCycle is able to generate Pareto-optimal radiotherapy
treatment plans by the use of a user-defined, cancer site specific wish list without any
human interaction (cf. 3.1.1).
Currently, this method is used in automated plan generation for patients with prostate
cancer [21] and head-and-neck and cervical cancer[24]. The conclusion of the mentioned
studies was that even an expert dosimetrist, in the absence of time pressure, could not
beat the procedure for fully automated plan generation. In this study its use has been
extended to lung cancer treatment and the clinical introduction has been started.
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2.4 Goal of the study
The aim of this study was to employ Erasmus-iCycle to develop a fully automated
treatment planning procedure to generate VMAT plans for stage III/IV non-small cell
lung cancer patients, treated with curative intent, and to compare them with manually
generated, clinically delivered IMRT plans for a large set of patients. Since VMAT was
not used in clinic yet, it was requested to an expert dosimetrist to generate a limited
number of VMAT plans without the use of iCycle and any prior knowledge about the
delivered plan to assess a comparison in plan quality between automatically and manually
generated VMAT plans. The whole study was performed in cooperation with two medical
physicists and two oncologist physicians, who supplied for the indispensable clinical
feedback to the work.
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Chapter 3
Methods and materials
3.1 Background: system for automated planning
3.1.1 Erasmus-iCycle
Erasmus-iCycle is an in-house developed algorithm for multi-criteria optimization of
beam intensity profile (IMRT, cf. 1.5.2.2) and beam angles. iCycle has been developed
at Erasmus Medical Center Cancer Institute since 2012[25] and represents a powerful
tool in an automated planning strategy. Since iCycle is not a treatment planning system
(TPS), i.e., it is not able to directly give input to the delivery machines, this software
is used in combination with the Elekta TPS Monaco (cf. 3.1.7) to generate actually
deliverable radiotherapy treatment plans. A diagram of the entire procedure is shown in
Fig. 3.1.
3.1.2 Multi-criterial optimization
Radiotherapy treatment planning is a problem with a high level of complexity. The
optimization problem consists of different, conflicting goals. On the one hand the tumor
should receive a certain minimal dose level, while the surrounding healthy tissues, that
all have specific different tolerances of radiation, should receive as little dose as possible.
Therefore, in multi-criterial optimization, multiple objectives are in competition with
each other, so that reaching one objective can lead to not fully fulfilling the others.
Typically, no single optimal solution exists that simultaneously optimizes each objective.
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Figure 3.1: Diagram of the automated planning procedure
A solution is called Pareto-optimal if none of the objective functions can be improved
without deteriorating other objective values. Without additional preference information,
all Pareto optimal solutions can be considered mathematically equally good: then, it
is necessary to introduce user-defined preferences in order to differentiate and choose
between various solutions.
3.1.3 Wish list
In iCycle the optimization operation is based on a user defined wish list which contains
hard constraints and objectives with given priorities. Every element of the wish list
consists of a specific cost function, a priority and a goal.
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• Constraints must be strictly met, otherwise the plan is considered invalid. It is
proper to consider that too strict constraints may limit possibilities to generate
attractive plans.
• Objectives are cost functions whose goals have to be met as much as possible
(without violating the imposed constraints).
In iCycle the objectives are optimized one by one in order of priority. Priorities play
a crucial role in determining the outcomes. In iCycle, a later objective is optimized as
far as it does not affect the result of the previous ones: even inverting priorities of two
objectives, especially for complex anatomies, may strongly affect the entire outcome.
3.1.4 Brief introduction to 2pεc optimization method
iCycle uses the 2pεc algorithm for prioritized optimization. The 2pεc algorithm,
proposed by Breedveld et al.[26], is an extension of the ε − constraint method[27], in
which one objective at a time is optimized while keeping the others (higher prioritized)
constrained. The method is extended to a 2 phase constraint optimization (2pεc), where
a goal can be assigned to each objective in the first phase of the optimization, while in
the second phase a full optimization of the objectives is applied.
Hard constraints and prioritized objectives are given in a wish list which completely
regulates the whole optimization process. The idea at the base of the approach is that
when it is possible to minimize the dose below a certain threshold (i.e., its goal) for one
objective, it is often more desirable to minimize the dose for the other (lower prioritized)
objectives first than to directly minimize the dose for the higher objectives to its fullest
extent.
The wish list defines hard constraints and a list of n objectives fi(x) characterized
by a priority i and a goal bi. During the first iteration of the first phase, the objective
having highest priority is optimized:
minimize f1(x)
subject to g(x) ≤ 0
f1(x) is the objective with priority 1 and g(x) is a vector which represents the list
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of the constraints which are to be met at all times. Based on the solution x∗ of this
optimization, a new bound for the optimized objective is defined and it is set as constraint
during the optimization of the following objective. The new bound is chosen according
to the following rule:
ε1 =
b1 if f1(x∗)δ < b1f1(x∗)δ if f1(x∗)δ ≥ b1
where b1 and ε1 are respectively the goal and the new bound of the objective with
priority 1, f1(x
∗) is the obtained value for the objective f1(x) and δ is a slight relaxation
to create some space for the subsequent optimizations (usually set to 1.03, i.e. 3%). In
practice this relaxation is mandatory to avoid the optimization algorithm from stalling
due to numerical problems. The next step is the optimization of the second objective,
f2(x), while the obtained result for f1 is added to the constraints list:
minimize f2(x)
subject to g(x) ≤ 0, f1(x) ≤ ε1
This is repeated for all n objectives.
In the second phase of the multi-criterial optimization, all the objectives which met
their goals are minimized to their fullest, while keeping all others constrained: so, for
each fi which met its goal bi, the following problem is solved:
minimize fi(x)
subject to g(x) ≤ 0, fk(x) ≤ εk, k ∈ {1, . . . , n}
3.1.5 Wish list generation
Many cost functions are available, allowing a large degree of freedom in the genera-
tion of the wish list. Any of them can be used in “minimize maximum” or “maximize
minimum” mode.
• Linear: when used in conjunction to minimize maximum, this cost function regu-
lates the maximum allowed dose. It is mainly employed to settle undesired over-
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doses and to strictly govern the maximum allowed dose to organs at risk character-
ized by serial complication mechanism (i.e., organs in which the cost of increasing
the dose to an already hot sub-volume rises tremendously, following a strongly
non-linear behavior, such as the spinal cord[28]
• Mean dose cost function
• Logarithmic tumor control probability (LTCP): LTCP is defined as
LTCP =
1
m
m∑
j=1
e−α(dj−D
P )
where m is the number of voxels in the target structure, DP is the prescribed dose,
dj is the dose in voxel j and α is the cell sensitivity parameter, in this study set to
0.8[19]. LTCP is able to guarantee a proper target coverage.
• Equivalent uniform dose (EUD): this function is regulated by the parameter k in
the formula
EUD = k
√√√√ 1
m
m∑
j=1
dkj
where m is the number of voxels in the target structure and dj is the dose in voxel
j. For k = 1 the meaning of EUD is the same as the arithmetic mean; for k > 1
the high dose regions gain more importance in the weighted sum and, ideally, for
k =∞, EUD is equal to the maximum dose in the structure.
• Dose-volume reference points: these cost functions try to force the DVH (cf. 1.4.6)
related to a certain structure to achieve the requested value. Due to non-convexity,
the use is discouraged because it may lead to sub-optimal solutions of the problem.
Wish lists are stored in .xml format by the in-house developed software Lucy. Within
the same wish list it is possible to define specific features of the optimization process,
such as conditions on beam angles selection, prescribed dose to the target, number of
fractions, and detailed resolution for selected structures.
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3.1.6 iCycle VMAT plan generation
iCycle is specifically suitable to IMRT plans because it does not need to define a priori
the number of orientations in a plan; beams are added sequentially, so if adding beams
does not longer result in clinically significant improvements, the process can be stopped.
The user can also select the Pareto optimal plan with the best trade-off between number
of beams used an plan quality. Nevertheless, it is possible to simulate VMAT delivery
mode with adequate accuracy: in this study, the preselected configuration consisted of
23 equi-angular beams. It was previously proven that further increasing the number of
beams increased calculation time but did not lead to an improve in plan quality[21].
3.1.7 Treatment planning system: Monaco
iCycle is a very efficient tool that can be employed to investigate and find the optimal
dose distributions, as defined by a wish list. Nevertheless, to obtain deliverable treatment
plan it is needed to work in combination with a treatment planning system (TPS).
Monaco is a TPS developed by Elekta. The treatment planning system is used to
create treatment plans for any cancer patient for whom external beam IMRT or VMAT is
prescribed. Monaco offers many features, such as tools for structure contouring, enhanced
voxel property definitions, collection of biological and dose-based cost functions, Monte
Carlo simulation for dose calculation, and more.
The planning activity is based on inverse planning strategy, which requires a user
defined identification of the clinical goals in order to find the best configuration of beam
intensities, and the optimization process is organized in two phases. The first produces
the preliminary result, while the second stage converts ideal fluence to deliverable seg-
ments, using the same prescription defined in stage one. For this stage of optimization,
the Monte Carlo dose calculation algorithm is used to calculate the dose distribution.
For the description of the requirements and of the clinical goals, Monaco offers a set
of dose-based and biological cost functions. The set is composed of cost functions such
as target penalty, target EUD, serial model, parallel model, quadratic under/over dose,
under/over dose DVH, maximum dose and conformality. For details, cf. [29]. It is im-
portant to consider that during the optimization every cost functions receives a weight.
If the assigned weight exceeds a certain threshold, the objective turns to infeasible and
is not considered in the calculation anymore. Thresholds are cost function-specific and
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depend on the selected calculation modality: the Pareto mode allows higher weights to
cost functions referring to the target, the Constrained mode assigns higher thresholds to
organs at risk objectives.
Monaco is an efficient TPS but does not provide plan optimization functionalities.
Plan quality exclusively depends on the quality of the selection of the cost functions and
their goals that is made by the dosimetrist. Monaco does not consider different levels of
importance (i.e., priorities) between the objectives of the optimization list, so the cost
function goals should already be achievable values to obtain good RT plans. This is
exactly the task of iCycle as preoptimization of Monaco: to generate a list of feasible,
optimized dosimetric parameters, leaving Monaco with the assignment to elaborate the
best IMRT segments arrangement to reproduce the optimized dose distribution.
3.1.8 Export to Monaco
The reproduction of the iCycle optimized dose distribution is made by an automated
translation of the iCycle output into a Monaco template, i.e., a list of cost functions and
respective goals and parameters that leads the optimization process to the desired dose
distribution. The translation is realized by an in-house developed tool which is able to
make the whole process fully automated. The conversion, including possible multiplying
factors, is site specific and needs to be fine-tuned in a trial and error process (cf. 3.2.5).
3.2 Current study
3.2.1 Patients selection and target delineation
A set of consecutive locally advanced stage III-IV NSCLC patients treated between
January and August 2015 at Erasmus MC Cancer Institute were included in this study.
All patients were treated with curative intent. Patients who received prior radiotherapy
or surgery were excluded, leaving a total of 48 patients (Table 3.3).
A 4D CT scan was acquired and the 50% exhale phase was used for delineation of
the targets and OARs. The CTV of the primary tumor was generated by expanding
the GTV with a margin of 5 mm and was allowed to be edited manually. Affected
lymph nodes as determined on diagnostic CT scan and PET scan were encompassed by
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the CTV. The PTV was defined as the CTV of the primary tumor and lymph nodes
expanded by a margin of 1 cm. For patients with wide tumor motion the margin was
increased in the superior-inferior direction with individual margins.
Patients were treated with IMRT with 5 to 9 beams and according to one of three
different fractionation schedules with prescription doses varying between 30 Gy and 66
Gy depending on the capability to deliver the prescribed dose without violating the
clinical constraints. Treatment planning goals are shown in Table 3.1.
3.2.2 Clinical requirements for IMRT planning
The clinical requirements are given by the radiation oncologists; Erasmus MC guide-
lines are shown in Table 3.1. The clinical requirements can vary for different fractionation
regimens and, in particular, for the dose delivered per fraction; this is due to the tissue
ability of recovering the radiation damage during the inter-fraction time and to the regi-
men that patients are subject to in terms of chemo-radiotherapy. The 2 Gy per fraction
regimen is typical for concurrent chemotherapy, the 2.75 Gy is mostly used in cases of
sequential radiotherapy (cf.1.6.2).
During weekly meeting with physicians, it was experienced that not all the require-
ments were actually characterized by the same importance. Esophagus and heart could
be sacrificed to achieve a satisfactory PTV coverage; lungs-GTV V5Gy had lower priority
compared to obtaining a high level of plan conformality. These OARs requirements were
therefore to be intended as objectives, following the iCycle terminology (cf. 3.1.3).
Table 3.1: Clinical requirements for NSCLC
Organ 66 Gy 66 Gy 60 Gy 50 Gy Volume/
33× 2Gy 24× 2.75Gy 20× 3Gy 20× 2.5Gy Dose
Spinal Cord 50.0 Gy 49.3 Gy 46.3 Gy 46.3 0 cc
Esophagus ≤ 25% ≤ 25% ≤ 25% ≤ 25% V45Gy
Heart 40 Gy 40 Gy 40 Gy 40 Gy < 100%
50 Gy 50 Gy 50 Gy 50 Gy < 66%
66 Gy 66 Gy 66 Gy 66 Gy < 33%
Plexus 66.0 Gy 60.0 Gy 56.6 Gy 56.6 Gy < 1%
Continued on next page
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Table 3.1 – Continued from previous page
Organ 66 Gy 66 Gy 60 Gy 50 Gy Volume
33× 2Gy 24× 2.75Gy 20× 3Gy 20× 2.5Gy Dose
Lungs - GTV 20 Gy 20 Gy 20 Gy 20 Gy < 35%
5 Gy 5 Gy 5 Gy 5 Gy < 60%
≤ 20 Gy ≤ 20 Gy ≤ 20 Gy ≤ 20 Gy Mean Dose
GTV 95− 107% 95− 107% 95− 107% 95− 107% Target Dose
62.7 Gy 62.7 Gy 57 Gy 57 Gy D2cc
(95% P.D.) (95% P.D.) (95% P.D.) (95% P.D.)
< 1% < 1% < 1% < 1% V110%
CTV 95− 107% 95− 107% 95− 107% 95− 107% Target Dose
62.7 Gy 62.7 Gy 57 Gy 57 Gy D2cc
(95% P.D.) (95% P.D.) (95% P.D.) (95% P.D.)
< 1% < 1% < 1% < 1% V110%
PTV 95− 107% 95− 107% 95− 107% 95− 107% Target Dose
59.4 Gy 59.4 Gy 54 Gy 54 Gy D2cc
(90% P.D.) (90% P.D.) (90% P.D.) (90% P.D.)
> 95% > 95% > 95% > 95% V95%
< 1% < 1% < 1% < 1% V110%
Table 3.1 - End
3.2.3 Automated treatment planning with Erasmus-iCycle
Automated treatment planning was implemented as a two-step approach. First, 23
equiangular beams IMRT treatment plans were generated with Erasmus iCycle, our
in-house developed multicriterial dose distribution optimizer. Next the plans were auto-
matically converted into patient specific Monaco templates and the resulting deliverable
Monaco plans were saved for review.
3.2.4 Construction of the wish list
All the iCycle plans were obtained by employing one fixed wish list. Only minor
changes for different prescription doses and/or fractionation regimens were applied. This
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wish list was developed through the teamwork with oncologist physicians and medical
physicists during weekly meetings throughout the whole stay at Erasmus MC Cancer
Institute. The wish list was established and fine-tuned by applying an iterative procedure
of automated planning, plan evaluation by the physicians and wish list adjustments on
a training set of 7 patients (Table 3.3). The development proceeded until no further
improvements in plan quality could be observed.
The final wish list is shown in Fig. 3.2. The 8 constraints were employed to keep
general overdose below the threshold of 107% of the prescribed dose (A) and to set
specific fractionation dependent maximum dose constraints for spinal cord and plexus.
A mean dose constraint was applied to the lungs at 19 Gy, slightly below the clinical
requirements, to leave the process with some room for the translation to Monaco (cf.
3.2.5).
First priority was CTV and PTV coverage. It was previously proved that the use
of the LTCP cost function (cf. 3.1.5) is able to ensure a proper target coverage. The
sensitivity value α was set to 0.8, as suggested by previous studies[19]. When the spinal
cord was close to the target or overlapped it, the objective was applied to the target to
which the spinal cord expanded by 5 mm was subtracted. This happened to steer the
acceptable underdosage to the part of the PTV/CTV closest to the spinal cord.
An objective with priority 3 aimed to reduce the maximum dose 4 cm far from the
PTV at 60% of the prescribed dose. This was followed by an objective for further
reduction in mean lungs dose and two more objectives (Shell PTV +1cm and Shell
PTV +3cm) with priorities 5 and 6 to realize a steep dose fall-off outside the PTV. To
minimize the esophagus volume treated to a high dose, an equivalent uniform dose (EUD,
cf. 3.1.5) objective with parameter k = 8 and an esophagus mean dose objective were
used (priority 7 and 8). Further reduction in MLD, mean heart dose and other OARs
dosimetric parameters were applied from objectives 9 to 13. In the first phase of the
2pεc optimization (cf. 3.1.4) objective functions were minimized, when possible, to the
corresponding goal in the wish list; in the second phase, all objectives were consecutively
minimized to their fullest extent.
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Figure 3.2: iCycle wish list for lung cancer treatment
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3.2.5 Conversion to Monaco
The multicriterially optimized dose distribution obtained with iCycle was used to feed
a template for the TPS Monaco, i.e., a list of cost functions whose goals (isoconstraint)
were determined by the iCycle output, to reproduce the same dose distribution in a
deliverable treatment plan. The iCycle plan could not be directly used as treatment plan
because of the absence of a leaf sequencing algorithm (i.e., an algorithm that simulates
a real multi leaves collimator) and the employment of a pencil beam dose simulation
algorithm that was mirrored in small inaccuracies in the final patient dose distribution
when compared to a Monte Carlo simulation. Small discrepancies could be observed
especially in tissue inhomogeneities. The translation followed a standard procedure at
Erasmus MC Cancer Institute previously successfully tested on other cancer sites[21].
The only significant difference lied in the need of a 5% relaxation of the iCycle achieved
mean lungs dose and V20Gy (cf. 3.1). Since a site-specific translation was not investigated,
secondary improvements in this stage of the work cannot be firmly excluded.
Table 3.2: Details for automated generation of Monaco templates
Structure Cost function Parameter Goal
PTV-CORD+5
Quadratic Overdose 109% P.D. 0.500
Underdose DVH 95% P.D.
98.5% iCycle
achieved V95
Target Penalty P.D.
Lungs - GTV
Serial 1 105% iCycle achieved
mean dose
Parallel
105% iCycle
45%
achieved mean dose
Overdose DVH 20 Gy
105% iCycle
achieved V20Gy
Overdose DVH 5 Gy
105% iCycle
achieved V5Gy
Continued on next page
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Table 3.2 – Continued from previous page
Structure Cost function Parameter Goal
Heart
Serial 1
iCycle achieved
mean dose
Parallel
iCycle achieved
45%
mean dose
Esophagus
Serial 1
iCycle achieved
mean dose
Parallel
iCycle achieved
45%
mean dose
Plexus Left Maximum Dose 65.0 Gy
Plexus Right Maximum Dose 65.0 Gy
Spinal Cord Maximum Dose
iCycle achieved
maximum dose
Patient
Maximum Dose 109% P.D.
Shell 1 cm
80% iCycle achieved
maximum dose
Shell 3 cm
80% iCycle achieved
maximum dose
Shell 4 cm
80% iCycle achieved
maximum dose
Conformality 0.80
Table 3.2 - End
3.2.6 Validation procedure and statistical testing
The automated procedure was validated on a set of 41 patients consecutively treated
between January and August 2015 (cf. 3.2.1). The list of patients and fractionation
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schedules are shown in Table 3.3 and Fig. 3.3. Plan quality was assessed by the radi-
ation oncologists and automated plans were compared to clinical plans by the use of a
list of dosimetric indicators selected by the physicians. Statistically significance of the
differences was evaluated with a two tailed Wilcoxon signed rank test. A p < 0.05 was
considered as statistically significant.
Table 3.3: Prescribed doses and fractionation regimens. Latin enumeration indicates the
patients employed as training set.
n Patient ID Prescribed Number of Dose per fraction
dose (Gy) planned fractions (Gy)
I GDGNSCLC3 66 33 2
II GDGNSCLC4 66 33 2
III GDGNSCLC6 66 33 2
IV GDGNSCLC8 66 33 2
V GDGNSCLC9 66 33 2
VI GDGNSCLC10 66 33 2
VII GDGNSCLC13 66 33 2
1 GDGCProspIM1 39 13 3
2 GDGCProspIM2 60 30 2
3 GDGCProspIM3 66 33 2
4 GDGCProspIM4 66 33 2
5 GDGCProspIM5 60.5 22 2.75
6 GDGCProspIM6 45 15 3
7 GDGCProspIM7 60 30 2
8 GDGCProspIM8 66 33 2
9 GDGCProspIM9 66 33 2
10 GDGCProspIM10 66 33 2
11 GDGCProspIM11 45 15 3
12 GDGCProspIM13 66 33 2
13 GDGCProspIM18 66 24 2.75
14 GDGCProspIM19 60.5 22 2.75
Continued on next page
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Table 3.3 – Continued from previous page
n Patient ID Prescribed Number of Dose per fraction
dose (Gy) planned fractions (Gy)
15 GDGCProspIM20 66 33 2
16 GDGCProspIM21 45 15 3
17 GDGCProspIM22 66 33 2
18 GDGCProspIM24 66 24 2.75
19 GDGCProspIM25 66 33 2
20 GDGCProspIM26 60.5 22 2.75
21 GDGCProspIM27 66 24 2.75
22 GDGCProspIM28 55 20 2.75
23 GDGCProspIM29 66 24 2.75
24 GDGCProspIM30 45 15 3
25 GDGCProspIM31 66 33 2
26 GDGCProspIM32 57.75 21 2.75
27 GDGCProspIM33 66 24 2.75
28 GDGCProspIM34 66 24 2.75
29 GDGCProspIM35 30 10 3
30 GDGCProspIM36 66 24 2.75
31 GDGCProspIM37 66 24 2.75
32 GDGCProspIM38 66 24 2.75
33 GDGCProspIM39 66 33 2
34 GDGCProspIM40 66 33 2
35 GDGCProspIM41 60 30 2
36 GDGCProspIM42 45 15 3
37 GDGCProspIM43 66 33 2
38 GDGCProspIM44 60 30 2
39 GDGCProspIM45 66 33 2
40 GDGCProspIM46 45 15 3
41 GDGCProspIM47 66 24 2.75
Table 3.3 - End
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Figure 3.3: Validation set of patients
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3.2.7 Comparison with manually generated VMAT plans
Since VMAT was not introduced in clinical routine at the time of the study, all the
41 comparisons were made with respect to clinically delivered IMRT plans. To perform a
comparison with manually generated plans with the same delivery modality, it was asked
an experienced dosimetrist to generate VMAT plans from scratch without any previous
knowledge about the iCycle output or the IMRT clinical plans. Plans were made for a
subset of ten randomly selected patients. The required time for each plan was at about
3-4 hours.
3.2.8 Dose escalation
When during the manual planning procedure it was not possible to achieve the full
dose of 66 Gy without violating at least one of the clinical constraints, the number
of planned fractions, and consequently the prescribed dose, was reduced following a
clinical schedule. Dose was reduced from 66 Gy to 60 Gy or 60.5 Gy depending on
the fractionation schedule. When even a dose of 55 Gy was not feasible, the applied
schedule was a prescription dose of 45 Gy delivered in 15 In few cases lower doses were
prescribed (cf. 3.2.6). Intermediate reductions of the number of planned fractions were
not clinically investigated due to working time limitation. Nevertheless, the automated
procedure would easily allow to generate plans for fraction-by-fraction dose reduction
without increase of the operator workload, at least at the iCycle pre-optimization stage.
3.2.9 Delivery machines
The treatment plan will be delivered on an Elekta Sinergy system (Fig. 3.4). The
machine offers a total field size of 40× 40 cm2 equipped with an MLCi2 (2× 40 leaves of
1 cm) with active leakage reduction. For positioning verification, the machine is equipped
with MV and kV imaging.
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Figure 3.4: Elekta Sinergy system
3.3 Considerations about the iCycle wish list
3.3.1 Random sampling in iCycle optimization
During the iCycle optimization, the goals of the maximum dose constraints were set
at about 5% lower than what requested by the clinical requirements (Fig. 3.2 and Table
3.1). This precaution was adopted because, during the optimization process, iCycle
randomly sampled only a certain percentage of the voxels in a structure; especially when
dealing with maximum dose constraints, this meant that it was not strictly excluded to
have a negligible number of voxels which exceeded the requirement. For the same reason,
the maximum dose constraint at 107% of the prescribed dose was repeated on several
structures (i.e., patient, CTV, PTV). With this precaution it was easily increased the
number of sampled voxels into the target structures (i.e., where high dose was expected).
3.3.2 Scattering length
iCycle dose distributions could not be identically reproduced by the treatment plan-
ning system, mainly because iCycle was not equipped with a leaves sequencing algorithm
and because it employed a pencil beam dose simulation algorithm, due to a reduced com-
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putation time requirement, while Monaco was based on a Monte Carlo dose simulation
algorithm, which was as a whole judged as more accurate and reliable. Discrepancies
between the two dose simulation algorithms could be revealed when dealing with tissue
inhomogeneities, i.e. very high density tissues (like bones) or very low density tissues
(such as the lungs). Especially in lung cancer dose distributions, it was found an under-
estimation of the lateral scattering of the photons in the pencil beam calculation; this
meant that the low dose region was smaller than what estimated by the Monte Carlo
algorithm and this was mirrored, for instance, in a higher V5Gy in the healthy lungs
structure. The problem was tackled by doubling the scattering length, i.e. the radius
into which the scattering phenomena were simulated, from the standard iCycle setting
of 30 mm to 60 mm, and by relaxing the requirements in the translation from the output
of iCycle to the Monaco template (Table 3.2).
3.3.3 Conformality and mean lung dose reduction
In the developed wish list (Fig. 3.2) the third objective focused on conformality in
terms of reducing the maximum dose 4 cm far from the PTV to 60% of the prescribed
dose. Fourth objective operated on a further mean lung dose reduction to 15 Gy. This
disposition was selected because, as tested, just switching the priorities of these two
objectives resulted in iCycle plans with little hot spots far from the PTV.
3.3.4 PTV minus expanded spinal cord (5 mm)
As shown in section 3.2.4, the second objective in the final wish list was applied to
the PTV structure to which the spinal cord, expanded by 5 mm, was subtracted. Since
the maximum dose constraint on the spinal cord was significantly far from the prescribed
dose (between 46.3 Gy and 50 Gy, depending on the fractionation regimen), it was not
feasible to achieve the PTV LTCP goal when the spinal cord was close or overlapping
the PTV. In fact, LTCP arose tremendously in presence of wide underdosed areas. The
conflict between the spinal cord constraint and the goal of the first objective led the
optimizer to waste the entire optimization room in trying to lower as much as possible
the LTCP (with goal set to 1), obtaining inhomogeneous dose distribution in the PTV.
The subtraction of the expanded spinal cord did not affect plans in which the spinal cord
was far from the PTV but allowed to steer the unavoidable, acceptable, underdosage
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closer to the spinal cord (Fig. 3.5). The margin of 5 mm was selected by testing several
values.
Figure 3.5: Comparison between a plan in which the LTCP cost function is applied to
the entire PTV (left) and a plan in which LTCP cost function is applied to PTV minus
spinal cord expanded by 5 mm (right). Both plans are iCycle dose simulations. In the
second plan the underdosed region is steered toward the spinal cord. Dose distribution
on the PTV (red contour) is more conformal and homogeneous.
3.4 Evaluation tools: DVHs and scatterplots
A cumulative dose volume histogram (DVH) was a histogram in which the total
volume receiving a dose greater than, or equal to, a given dose was plotted against dose
(cf. 1.4.6). DVHs were used to compare different treatment plans to the same patient.
Nevertheless, since they did not bring any spatial information about the dose, their
analysis should always be supported by a careful observation of the dose distributions
on the patient slice by slice.
The strength of DVHs was their ability in giving clear messages about the dose
distribution at the first sight. An example is shown in Fig. 3.6. The interpretation of
these diagrams strongly depended on the organs they aimed to describe.
• Target structures (GTV, CTV, PTV, cf. 1.4.4): since the aim of the plan was to
ensure the highest target coverage, the DVH should take place as much as possible
on the upper right side of the plot. Furthermore, an important desired feature of the
target dose distribution was homogeneity: this meant that, although underdose was
harmful in terms of fighting the tumor, also overdosage was considered dangerous
and should be rejected. In terms of DVHs, both properties were expressed by the
steepness of the curve. Summarizing, the DVH for a target structure should be
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as similar as possible to a step function placed on the prescription dose or slightly
beyond it.
• Parallel complication mechanism structures (healthy lungs, esophagus, heart): for
these structures the organ function could be maintained by a sufficiently large
critical volume while the remaining volume could be sacrificed when needed. This
was often mirrored by objectives on keeping the irradiated volume under certain
thresholds at some reference doses, such as 20 Gy and 5 Gy for the healthy lungs
(Table 3.1). The DVH curve should be as low as possible, but it was generically
not possible to avoid either low dose to a wide region and/or high dose to a small
area.
• Serial complication mechanism structures (spinal cord, plexus): for these organs
(cf. 3.1.5) the only critical parameter was the maximum dose; DVH shape was
substantially irrelevant.
Figure 3.6: Example of DVH. Target DVHs (PTV, CTV) follow the shape of a step
function, while OARs DVHs should be kept as low as possible.
From a DVH it was possible to extract dose volume reference points, expressed as
volume receiving at least a reference dose (VrefGy) or a percentage of the prescribed dose
(Vref ), or as dose delivered to at least a reference volume (Dref ) (cf. 1.4.6). Scatter-
plots were considered an useful tool to compare a large set of coupled plans (such as
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Figure 3.7: Example of scatterplot for esophagus mean dose. Points lie almost always in
the lower right corner, that is where the value achieved in the clinical plan is higher than
for the MonacoVMAT plan. This behaviour show an improvement in esophagus sparing
by the automated plan.
the comparison between clinically delivered plans and automated plans for this study).
Scatterplots showed one, or more than one, dose volume reference point for a certain
structure, assigning the two axes to the two groups of plans to compare and plotting
the bisector line, representing the equivalence line. A point was therefore plotted with
coordinates (x, y) = (plan 1, plan 2). In our notation, the x-axis was assigned to the
clinical plan and y-axis to the automated plans. For scatterplots representing dose vol-
ume reference points describing the target coverage, the aim was then to obtain points
characterized by y > x, that is lying in the upper left corner of the plot. On the other
hand, plotting organs at risk reference points yearned for placing the points in the lower
right corner of the figure, that is x > y. An example is shown in Fig. 3.7.
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3.5 Uncertainties
In radiotherapy treatment planning a proper uncertainties assessment is often a hard
task. Uncertainties could be mainly divided in dosimetric and anatomical uncertainties.
A dosimetric validation of the employed treatment planning system was previously
performed, proving that the dose distributions measured in either water or in anthro-
pomorphic phantoms were well within acceptance limits of 2% or 2 mm distance-to-
agreement[31].
Anatomical uncertainties evaluation should consider several factors, including tumor
shrinkage within the treatment cycle and intra-fraction motion due to free breathing
condition of the patient during the dose delivery. This analysis was inapplicable to our
patients, since the availability of the single 50% expiration images set only. Neverthe-
less, in clinical practice only the dose calculated on this image acquisition is evaluated.
Previous studies[32] based on IMRT plans for locally advanced NSCLC proved that the
observed dosimetric variations in PTV V95, MLD and lungs V20Gy were small on aver-
age (2.5%, 3.1%, 2.2% respectively); nevertheless, the interfractional changes in tumor
volume, mobility, and patient setup was sometimes associated with dramatic dosimetric
consequences. A consequence was the recommendation of the introduction of adaptive
radiotherapy in NSCLC treatment. Adaptive radiotherapy (ART) aims at adjusting the
treatment plan during the treatment cycle to ensure proper target coverage and to re-
duce normal tissue complications. In the adaptive process, the changes are monitored
systematically for the individual patients and when predetermined criteria are violated,
an adaptive treatment plan is made [33].
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Chapter 4
Results
4.1 Overview
With the applied wish list and automated conversion to Monaco plans, 85% (35/41)
of the automatically generated Monaco VMAT (autoVMAT) plans were clinically accept-
able as judged by two physicians. All the acceptable autoVMAT plans were evaluated as
better than the corresponding manually generated, clinically delivered IMRT plans, due
to a combination of a better PTV coverage, dose conformality and sparing of the lungs,
heart and esophagus. The remaining 6 plans violated at least one of the clinical con-
straints (Table 3.1), i.e., the PTV coverage (V95) and/or lungs minus GTV mean dose
(MLD) and V20Gy (cf. 4.6). All plans fulfilled the planning constraints for the spinal
cord, the heart and the plexus. The comparison between the autoVMAT and clinical
IMRT plans for all relevant dose statistics is shown in Figg. 4.1 and 4.2. Differences
between the clinical plans and the autoVMAT plans are plotted such that positive values
are in favor of the autoVMAT plans, that is the opposite value is plotted for the target
coverage (−PTV D99, −PTV V95) and the actual value of the difference is plotted for
the organs at risk. The displayed Wilcoxon test p-values were calculated over the entire
validation cohort of 41 patients. The pronounced predominance of positive bars confirms
the overall improvement in plan quality for autoVMAT plans compared to the clinically
delivered IMRT plans.
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Figure 4.1: Differences between clinical plans and autoVMAT plans for mean lung dose
(MLD), lungs V5Gy, lungs V20Gy, PTV D99% and PTV V95%. Positive values are in favor
for the autoVMAT plans. For visualization purposes the differences of the V5Gy and
V20Gy of the lungs and PTV D99 were multiplied by 0.1, 0.1 and 0.5 respectively.
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Figure 4.2: Differences between clinical plans and autoVMAT plans for esophagus mean
dose, heart mean dose, conformity index R50 and homogeneity index (HI). Positive values
are in favor for the autoVMAT plans. For visualization purposes the differences of the
R50 and HI were multiplied by 10 and 100 respectively.
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4.2 PTV coverage
PTV coverage was assessed by the use of two dosimetrical parameters:
• PTV V95: the volume receiving at least 95% of the prescribed dose was the main
indicator of the target coverage. V95 was clinically constrained to be higher than
95% of the planning target volume.
• PTV D99: this parameter expresses the so called “near minimum dose”, i.e., the
dose delivered to at least 99% of the PTV.
PTV mean dose was not selected as quality index because the difference between two
plans could be strongly affected by different, unwanted, overdose. Evaluating the 35
acceptable autoVMAT plans with respect to the clinical IMRT plans, the average im-
provement in PTV V95 was 1.1% (SD=1.1%), while PTV D99 increased by 0.6 Gy (1.2%,
SD=1.5 Gy). Differences were statistically relevant (p < 0.001) for a Wilcoxon test. For
both PTV parameters, autoVMAT plans aimed to obtain higher results, that is a better
target coverage. In a scatterplot as Fig. 4.3, points should lie above the equality line,
i.e., in the sector where y > x. This behaviour was especially showed in the V95 plot, in
which in only three cases (two of which were labelled as unacceptable plans) the cover-
age achieved with the automated procedure was lower than what previously achieved by
manual planning in the IMRT clinical plan. The D99 range of values was wide due to
the several prescription doses in the validation set (from 30 Gy to 66 Gy).
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(a) (b)
Figure 4.3: Scatterplots of PTV D99 (a) and PTV V95 (b). Red circles indicate the
plans that were not clinically acceptable. Points lying above the equality line show
improvement for autoVMAT plans.
4.3 Lungs minus GTV
The healthy lung tissue was often the most dose limiting organ at risk. The dose to
this organ was measured by:
• Mean lungs minus GTV dose (MLD): the clinical constraint at Erasmus MC was
set to 20 Gy for NSCLC treatment.
• Lungs V20Gy: 20 Gy was considered an important threshold for lung tissue func-
tionality. Lungs V20Gy had to be lower than 35% of the volume.
• Lungs V5Gy: the clinical requirements list stated as maximum volume 60% of the
total healthy lung volume, but in practice this threshold was often raised to 70%.
It was also experienced during the meetings with the physicians that, since the
V5Gy was lower than 60%, it was better to focus on other organs sparing or on
achieving a higher level of conformality.
Mean lung dose in the 35 acceptable autoVMAT plans was reduced on average by
0.9 Gy (4.6%, SD=1.0 Gy, p < 0.001); the average difference in lungs V20Gy was 1.3%
(SD=2.1%, p < 0.001) in favor of the automated plans. For lungs V5Gy an average
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reduction of 3.2% was observed (SD=7.6%, p = 0.029). As well as for the other organs
at risk, points lying below the equality line showed a better sparing for autoVMAT plans
with respect to clinical IMRT ones (Fig. 4.4). In consideration of the above, lungs V5Gy
distribution was more scattered than others (Fig. 4.4(c)).
(a) (b)
(c)
Figure 4.4: Scatterplots of lungs minus GTV mean dose (a), V20Gy (b) and V5Gy (c).
Red circles indicate the plans that were not clinically acceptable. Points lying below the
equality line show improvement for autoVMAT plans.
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4.4 Esophagus and heart
Esophagus and heart were organs at risk that were not characterized by clinical
constraints, i.e., a plan was not rejected due to exceeding a clinical goal for these organs.
Evaluation was made taking into account the following parameters:
• Mean esophagus dose
• Esophagus V45Gy: the esophagus was sensitive to high dose, so it was necessary to
monitor the volume receiving at least 45 Gy, that should be kept below 25% of the
total volume.
• Mean heart dose: the heart was considered a low priority organ at risk, mainly
because the toxicity effects showed after several years.
Considering the 35 acceptable autoVMAT plans, esophagus mean dose was reduced
on average by 3.6 Gy (15%, SD=2.8 Gy, p < 0.001) and V45Gy decreased by 4.6%
(SD=4.9%, p < 0.001) with respect to the clinical IMRT plans. Heart mean dose showed
a reduction of 1.5 Gy (13%, SD=1.8 Gy, p < 0.001). Scatterplots for these dose statistics
are shown in Fig. 4.5.
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(a) (b)
(c)
Figure 4.5: Scatterplots of esophagus mean dose (a), esophagus V45Gy (b) and heart mean
dose (c). Red circles indicate the plans that were not clinically acceptable. Points lying
below the equality line show improvement for autoVMAT plans.
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4.5 Dose conformality and target dose homogeneity
Dose conformality and target dose homogeneity were assessed by the following in-
dexes:
• R50: the ratio between the total volume receiving at least 50% of the prescribed
dose (patient V50) and the planning target volume.
• Homogeneity index (HI): the HI was an objective parameter to assess the homo-
geneity in the distribution of the dose to the PTV and the steepness of the PTV
DVH, defined as:
HI =
D2 −D98
D50
For both indexes a reduction showed an improvement in plan quality (Fig. 4.6). An
average reduction of 10.5% (SD=10.7%, p < 0.001) and 0.025 (22%, SD=0.017, p <
0.001) in the 35 acceptable autoVMAT plans with respect to the corresponding clinical
IMRT plans was observed respectively for R50 and HI.
(a) (b)
Figure 4.6: Scatterplots of R50 (a) and homogeneity index (b). Red circles indicate
the plans that were not clinically acceptable. Points lying above the equality line show
improvement for autoVMAT plans.
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4.6 Unacceptable plans
In six cases (15% of the validation patients set), autoVMAT plans were not deemed
clinically acceptable, due to a violation of at least one clinical constraint. In two cases
PTV coverage was not acceptable (V95 < 95%, V90 < 99%); in three cases MLD and
lungs V20Gy exceeded the clinical constraint of 20 Gy and 35% respectively; in one case
only V20Gy violated the clinical goal. For all six plans that were initially not acceptable
plans, it took a dosimetrist less than 10 minutes hands-on time to manually fine-tune the
VMAT plan in Monaco to make it acceptable by applying slight changes to the Monaco
cost functions list. In contrast, to generate a VMAT plan from scratch 3-4 hours were
required. Dose statistics that violated the clinical constraints are shown in Table 4.1. The
existence of unacceptable plans could be mainly ascribed to an inappropriate translation
of the iCycle plan into a Monaco template; an example is reported in section 4.9.2.
Table 4.1: Dose statistics that violated the clinical constraints for the six unacceptable
plans
Patient ID Structure Dose statistics
GDGCProspIM1 PTV V90 = 96.5%
V95 = 94.3%
GDGCProspIM2 Lungs minus GTV MLD = 21.2 Gy
V20Gy = 39.3%
GDGCProspIM5 Lungs minus GTV V20Gy = 36.9%
GDGCProspIM31 Lungs minus GTV MLD = 20.6 Gy
GDGCProspIM41 Lungs minus GTV MLD = 20.9 Gy
GDGCProspIM42 PTV V90 = 96.6%
V95 = 92.3%
82
4.7 AutoVMAT vs manual VMAT planning
For a subset of ten patients an experienced dosimetrist prospectively planned VMAT
plans in Monaco without prior knowledge of the corresponding Erasmus-iCycle output or
the clinically used IMRT plan. AutoVMAT plans were judged by a radiation oncologist
as equivalent or better in quality with respect to manually generated VMAT plans for all
the patients in the subset. Average differences were not statistically significant, except for
lungs V5Gy (p < 0.02), esophagus mean dose (p < 0.02) and esophagus V45Gy (p < 0.02),
all in favor of the autoVMAT procedure, and conformity index R50 (p = 0.029), in favor
of the manually generated plans, although the sample was limited to 10 elements.
Differences between manually generated VMAT plans and autoVMAT plans are re-
ported in Table 4.2. In figure 4.7 and 4.8 scatterplots are shown for the main dose
statistics. Points in the scatterplots were on average equally distributed on both sides of
the equivalence line. Furthermore, a reduction in PTV coverage was often coupled with
a better sparing of the lungs and vice versa; this meant that both plans took place in
proximity of the Pareto-optimality boundary, i.e., an objective could be improved only
at the cost of a loss in the achieved value of another objective.
Table 4.2: Dose statistics comparisons between autoVMAT and manually generated
VMAT plans
Structure Dose metric ManualVMAT-AutoVMAT St. Dev.
PTV V95 -0.3% 1.4%
PTV D99 0.0 Gy 1.8 Gy
Lungs minus GTV Mean dose 0.2 Gy 1.0 Gy
Lungs minus GTV V20Gy 0.5% 2.2%
Lungs minus GTV V5Gy 6.3% 3.2%
Esophagus Mean dose 2.2 Gy 1.8 Gy
Esophagus V45Gy 3.2% 2.2%
Heart Mean dose 0.2 Gy 1.1 Gy
R50 -0.33 0.37
HI 0.010 0.019
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(a) (b)
(c) (d)
(e)
Figure 4.7: Scatterplots of PTV D99 (a), PTV V95 (b), lungs minus GTV mean dose (c),
V20Gy (d) and V5Gy (e).
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(a) (b)
(c) (d)
(e)
Figure 4.8: Scatterplots of esophagus mean dose (a)
and V45Gy (b), heart mean dose (c), R50 (d) and homogeneity index (e).
85
4.8 Dose escalation
For 6 out of 11 patients with a prescription dose of less than 66 Gy in the clinical
plan, it was possible to escalate the tumor dose and obtain acceptable plans as judged by
a physician with the use of the automated plan generation procedure without exceeding
any of the clinical constraints. For two patients dose escalation from 45 Gy to 55 Gy
was possible, for other patients from 55 Gy to 60 Gy, 60 Gy to 66 Gy (two patients),
and 60.5 Gy to 66 Gy, respectively. When achieved within the clinical requirements, a
higher dose was always evaluated by a physician as an improvement in terms of tumor
fight.
4.9 Examples
4.9.1 Clinical plans, iCycle plans, AutoVMAT plans
The automated planning procedure required an image set, selected at 50% of the
expiration phase, on which the organs at risk and the target volumes were delineated.
Views were available in axial, sagittal and coronal mode (Fig. 4.9), although the axial
view (Fig. 4.9(a)) was the most employed by the radiation oncologist during the eval-
uation. The image set for patient GDGCProspIM7 was composed by 148 slices in the
axial view. The PTV spreaded from slice 67 to 116. The clinically prescribed dose was
60 Gy in 30 fractions due to impossibility in the manual planning procedure to achieve
the prescription dose of 66 Gy without violating any of the clinical constraints.
For each patient, three plans were available: the clinical IMRT plan, the iCycle
plan, that simulated the VMAT delivery mode with an IMRT setting of 23 equiangular
beams (cf. 3.1.6), and the actually deliverable VMAT plan in Monaco (autoVMAT). A
comparison between the three dose distribution is shown in the following Table 4.3.
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(a) (b) (c)
Figure 4.9: Image set and volumes delineation for patient GDGCProspIM7 in axial (a),
sagittal (b) and coronal view (c)
Table 4.3: Comparison between dose distributions of clinical plan, iCycle plan and au-
toVMAT plan for patient GDGCProspIM7. The percentage in the dose distribution
intensity scale is expressed in terms of the prescribed dose of 60 Gy.
Clinical plan iCycle plan AutoVMAT plan
Slice 70
Slice 78
Continued on next page
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Table 4.3 – Continued from previous page
Clinical plan iCycle plan AutoVMAT plan
Slice 86
Slice 94
Slice 102
Continued on next page
88
Table 4.3 – Continued from previous page
Clinical plan iCycle plan AutoVMAT plan
Slice 110
Table 4.3 - End
The clinical IMRT plan employed 6 beams with angles 0◦, 15◦, 180◦, 210◦, 270◦ and
340◦. The angle selection was based on the dosimetrist’s experience and could be sub-
optimal. For this patient, the employment of the 270◦ angle was a cause of the irradiation
of the contralateral lung (i.e., the opposite lung, with respect to the tumor site) with a
wide low-dose region. The dark blue region specified the area receiving at least 10% of
the prescribed dose of 60 Gy, i.e., 6 Gy.
The main information about the dose distribution were encompassed in the dose vol-
ume histograms (DVHs), the most useful tool for radiotherapy treatment plan evaluation
due to the ability to summarize a lot of information about the dose distribution in one
plot. DVHs for the clinical, the iCycle and the autoVMAT plans are shown in Figure
4.10.
The DVHs showed a better sparing of all the OARs (lungs-GTV, heart, esophagus) in
the iCycle and autoVMAT plans with respect to the clinical plan because the DVHs for
these organs were mainly lower than the solid line (clinical plan). On the other hand, for
those plans the DVHs referring to the target volumes (PTV, CTV) were shifted towards
the upper right corner and closer to the shape of a step function, meaning a better target
coverage and a more homogeneous dose to the target. The positive effects were enhanced
in the iCycle dose distribution with respect to the actually deliverable autoVMAT plan
due to dose simulation algorithm and the absence of the sequencing algorithm (cf. 3.2.5).
The strongest gain for automated planning was in lungs sparing, in particular in the
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Figure 4.10: Comparison between dose volume histograms of clinical plan (solid line),
autoVMAT plan (dashed line) and iCycle plan (dotted line) for patient GDGCProspIM7
low dose region, where V5Gy dropped from 70.2% (clinical plan) to 53.5% and 53.0% for
the iCycle plan and the autoVMAT plan respectively. This could be noticed directly
from the dose distribution by looking at the dark blue region (volume receiving at least
6 Gy) that covered the contralateral lung in the clinical plan, while this organ was almost
completely spared in the two automated plans. Also the healthy lungs mean dose was
remarkably spared from 19.0 Gy to 15.1 Gy and 16.1 Gy respectively in the iCycle and
autoVMAT plans. The difference of 1 Gy between the two automated plans was partially
ascribed to the translation from iCycle to Monaco, in which the value obtained after the
preoptimization was relaxed by 5%, i.e., 0.8 Gy. The most significant dose statistics are
reported in table 4.4.
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Table 4.4: Main dose statistics of the three plans for patient GDGCProspIM7
Structure Dose metric Clinical plan iCycle plan AutoVMAT plan
PTV V95 96.1% 98.8% 98.3%
PTV D99 55.9 Gy 56.7 Gy 56.0 Gy
Lungs - GTV Mean dose 19.0 Gy 15.1 Gy 16.1 Gy
Lungs - GTV V20Gy 31.0% 26.5% 28.2%
Lungs - GTV V5Gy 70.2% 53.5% 53.0%
Esophagus Mean dose 25.3 Gy 18.9 Gy 19.7 Gy
Esophagus V45Gy 31.7% 21.6% 22.9%
Heart Mean dose 9.2 Gy 8.4 Gy 8.1 Gy
4.9.2 Fixing unacceptable plans
Patient GDGCProspIM42 had a prescription dose of 45 Gy in 15 fractions. DVHs of
the main organs at risk and target volumes for the clinical plan and the iCycle plan are
shown in Fig. 4.11. The DVHs for the iCycle dose distribution showed a very remarkable
improvement in terms of healthy lung tissue, esophagus and heart sparing, while the PTV
coverage was comparable to the clinical plan (Table 4.5).
After the standard translation into a Monaco template, the plan obtained in Monaco
was judged as not acceptable by the physicians. In fact, while the lungs minus GTV
DVH was able to follow the shape of the one in the iCycle dose distribution, the target
coverage did not fulfill the clinical constraints (Fig. 4.12 and Table 4.5).
In this case, the level of agreement between the iCycle and Monaco dose simulation
algorithms was significantly lower than usual, so that, to achieve the goals for the lungs
minus GTV structure, the goals of the cost functions related to the target coverage in
the Monaco template were sacrificed and turned to infeasible (cf. 3.1.7) after short time.
In order to give Monaco more optimization room to properly achieve the goals about
the target coverage, the relaxation of the lungs minus GTV goal from iCycle to Monaco
was increased from 5% to 10% (cf. 3.2.5). The new obtained plan (labelled as autoV-
MATmod) fulfilled all the clinical constraints and was judged by the physician as better
than the clinical plan. DVHs and dose statistics are shown in Fig. 4.13 and Table 4.5. A
further investigation on the reason of the lower level of agreement between the two dose
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Figure 4.11: DVHs of the main organs at risk for the clinical plan (solid line) and the
iCycle dose distribution (dotted line) for patient GDGCProspIM42
Figure 4.12: DVHs of the main organs at risk for the clinical plan (solid line), the
iCycle dose distribution (dotted line) and the autoVMAT plan (dashed line) for patient
GDGCProspIM42
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distribution algorithms might lead to improvement in the percentage of the acceptable
plans in the automated procedure.
Figure 4.13: DVHs of the main organs at risk for the clinical plan (solid line), the
iCycle dose distribution (dotted line) and the autoVMAT plan after the relaxation in
the translation of the MLD (dashed line) for patient GDGCProspIM42
Table 4.5: Main dose statistics for the clinical plan, the iCycle plan, the autoVMAT with
the standard translation and the autoVMAT plan with the modified translation
Structure Dose metric Clinical iCycle AutoVMAT AutoVMATmod
PTV V95 97.3% 98.1% 92.9% 97.3%
PTV D99 41.5 Gy 41.8 Gy 37.0 Gy 40.8 Gy
Lungs - GTV Mean dose 18.2 Gy 15.2 Gy 15.6 Gy 17.2 Gy
Lungs - GTV V20Gy 35.7% 31.0% 31.1% 34.3%
Lungs - GTV V5Gy 62.7% 55.1% 55.5% 58.0%
Esophagus Mean dose 24.2 Gy 16.6 Gy 16.5 Gy 17.2 Gy
Esophagus V45Gy 6.2% 4.3% 2.5% 2.8%
Heart Mean dose 20.7 Gy 15.0 Gy 15.4 Gy 15.3 Gy
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4.9.3 Dose escalation
Patient GDGCProspIM44 had a prescription dose of 60 Gy in 22 fractions (2.75
Gy per fraction) because the dosimetrist could not achieve the prescription dose of 66
Gy without violating the clinical constraints related to the healthy lung tissue. The
autoVMAT plan obtained following the automated plan generation procedure was judged
by the physicians as remarkably better than the corresponding clinical plan, due to the
better PTV coverage and lungs sparing. It was interesting to notice that, while the
mean dose and the V20Gy decreased by 2.3 Gy and 5.5% respectively, the V5Gy increased
from 48.4% to 53.6%. Nevertheless, since this value was below the threshold of 60%,
the physicians accepted this loss. The reason of the different shapes of the DVHs of the
clinical plan and the autoVMAT plan could be found in the strongly different selection
of the beam directions. While the clinical plan employed six beam angles (0◦, 10◦, 180◦,
195◦, 220◦, 270◦, 340◦) mainly in the anterior-posterior direction (i.e., close to 0◦ and
180◦), the VMAT plan employed the full arc. This was mirrored in a wider low dose
region and, consequently, in a higher V5Gy for the lungs and a strongly lower shape of the
DVH at higher doses (Fig. 4.14), but also in a remarkably higher level of conformality
of the dose distribution (especially in slices 84 and 92).
Table 4.6: Dose distributions for the clinical IMRT plan (left) and the autoVMAT plan
(right) for patient GDGCProspIM44. The percentage in the dose distribution intensity
scale is expressed in terms of the prescribed dose of 60 Gy. The dose distribution in the
clinical plan is mainly placed along the anterior-posterior direction, while the autoVMAT
plan employs the full arc. This is mirrored in the automated plan by a higher level of
conformality and a better sparing of the lungs at medium and high dose, while the low
dose region increases.
Clinical plan AutoVMAT plan
Continued on next page
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Clinical plan AutoVMAT plan
Slice 68
Slice 76
Slice 84
Slice 92
Continued on next page
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Figure 4.14: DVHs for the clinical plan (solid line), the iCycle VMAT plan (dotted line)
and the autoVMAT plan (dashed line) for patient GDGCProspIM44 with a prescribed
dose of 60 Gy
For patient GDGCProspIM44 an attempt of dose escalation was made. The prescrip-
tion dose was increased to the full dose of 66 Gy. The automated procedure generated a
plan able to achieve a good target coverage with the increased prescribed dose without
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violating any of the clinical constraints. The DVH is shown in Fig. 4.15, while the main
dose statistics for the three plans are shown in Table 4.7.
Figure 4.15: DVHs of the clinical plan with a prescription dose of 60 Gy (solid line)
and autoVMAT plan with prescription dose increased to 66 Gy (dashed line) for patient
GDGCProspIM44
Table 4.7: Main dose statistics for clinical and autoVMAT plan with prescribed dose of
60 Gy and for autoVMAT plan with prescribed dose of 66 Gy. V95 refers to 57 Gy for
the first two plans and to 62.7 Gy for the last one.
Structure Dose metric Clinical AutoVMAT 60 Gy AutoVMAT 66 Gy
PTV V95 96.5% 99.1% 97.9%
PTV D99 54.7 Gy 56.5 Gy 61.0 Gy
Lungs - GTV Mean dose 19.6 Gy 17.3 Gy 19.8 Gy
Lungs - GTV V20Gy 33.2% 27.7% 31.2%
Lungs - GTV V5Gy 48.4% 53.6% 56.6%
Esophagus Mean dose 23.6 Gy 23.2 Gy 25.6 Gy
Esophagus V45Gy 32.0% 31.5% 32.9%
Heart Mean dose 10.9 Gy 10.8 Gy 11.6 Gy
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4.10 Further implications
4.10.1 Hands-on working time reduction
The employment of the automated procedure entailed a remarkable reduction in
hands-on working time for the dosimetrists. The working time requested to start the
process was at about 5 minutes and when manual fine tuning of the results was needed,
this was on average brief. As a whole, the overall hands-on working time decreased
from 3-4 hours to 10 minutes. Furthermore, plan quality was totally independent on
operator’s skills and experience.
4.10.2 VMAT employment
The automated procedure proved that using VMAT as delivery modality allowed to
achieve higher overall plan quality. The employment of VMAT technique reduced the
delivery time with respect to IMRT (from 20 to 8 minutes on average), with positive
effects in terms of less intra-fraction tumor and organs motion and more patient’s comfort
during the treatment.
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Chapter 5
Conclusions and perspectives
5.1 Conclusions
In this study the in-house developed optimizer Erasmus-iCycle was used to develop
a fully automated procedure for radiotherapy treatment planning of non-small cell lung
cancer. VMAT plans were automatically generated in combination with the treatment
planning system (TPS) Monaco and evaluated by two physicians. Comparisons were
made with respect to previously delivered, manually generated IMRT plans.
Since VMAT was not introduced in clinical practice at the time of the study, a
dosimetrist generated ten VMAT plans manually, without any prior knowledge about
the clinical IMRT plans or the autoVMAT plans. Plans were evaluated by a physician
and compared to the corresponding autoVMAT ones.
On a subset of patients for whom the prescribed dose was reduced in clinic to avoid
violations of the clinical constraints a dose escalation following the clinical schedules was
performed.
The main conclusions of the study are summarized below.
• The automated treatment planning procedure produced autoVMAT plans that
fulfilled all the clinical constraints in 85% of the cases (35 out of 41 patients).
• All the acceptable autoVMAT plans were judged by two radiation oncologists as
better than the corresponding clinically delivered IMRT plans, due to a combi-
nation of better PTV coverage, dose conformality and sparing of lungs, heart and
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esophagus. All average differences were statistically significant in a Wilcoxon signed
rank test.
• For the six automated VMAT plans that were initially not acceptable, it took a
dosimetrist less than 10 minutes hands-on time to manually fine-tune the VMAT
plan in our TPS to make it acceptable. In contrast, to generate a VMAT plan from
scratch 3-4 hours were required.
• An oncologist physician evaluated and compared autoVMAT plans with respect
to VMAT plans manually generated by an experienced dosimetrist. Overall plan
quality was equal or superior in autoVMAT plans. Average differences were mainly
in favor of the autoVMAT plans although mostly not statistically significant.
• The use of the automated procedure allowed to escalate the dose in 6 out of 11
plans of patients for whom the full tumor dose of 66 Gy was not clinically achievable
without violating the dose constraints. The increment was substantial (at least 5
Gy).
• The employment of the automated planning procedure allowed to reduce the hands-
on working time from 3-4 hours to at about 10 minutes per plan. The VMAT
delivery modality decreased the treatment delivery time from about 20 to about 8
minutes, with benefit for the patient.
5.2 Perspectives
5.2.1 VMAT and IMRT delivery modality
Since VMAT was not introduced in clinic at the time of the study, the comparisons
were mainly made with respect to clinically delivered IMRT plans. Consequently, it was
difficult to assess whether the overall improvement in plan quality was to be mainly
ascribed to the automation or to the different delivery technique. Nevertheless, the
test performed on the ten randomly selected patients reasonably proved that the overall
plan quality of autoVMAT plans was at least equal to the quality of plans manually
generated by an experienced dosimetrist. A comparison between clinically delivered and
automatically generated IMRT plans, without any clinical purpose and only for scientific
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interest, was outside the scope of the study and would have required the generation of a
different wish list.
5.2.2 Two-step approach and unacceptable autoVMAT plans
The automated planning procedure was based on a pre-optimization with Erasmus-
iCycle, followed by a conversion to a Monaco deliverable plan. After the conversion into
a Monaco plan, Pareto-optimality, the strong point of iCycle, was not proved anymore.
In fact, the Pareto-optimal solution was achieved in conditions of ideal fluence (i.e., in
absence of a leaves sequencing algorithm that simulated a real MLC) and with a simplified
pencil beam dose simulation algorithm. Nevertheless, plans took place very close to the
Pareto-optimality boundary, so that the autoVMAT plans could be interpreted as, at
least, a very good starting point in a treatment planning procedure. This meant that
only secondary or negligible improvements in plan quality could be achieved by an expert
dosimetrist starting from the autoVMAT plan results.
In the few cases of unacceptable plans, the reason could be ascribed to an inappro-
priate conversion into Monaco deliverable plans. In these plans, the level of agreement
between the iCycle output and Monaco was lower than the average and the conver-
sion needed stronger relaxation in some cost functions goals. Further investigation on a
site-specific conversion could lead to secondary improvements.
Improvements in the overall score could be achieved by equipping iCycle of a more
sophisticated dose simulation algorithm, in order to achieve pre-optimized dose distri-
bution with a higher level of agreement with actually deliverable dose distributions.
Even better, an intriguing way would be to develop a higher level of integration between
Erasmus-iCycle and Monaco.
5.3 Clinical introduction
The clinical introduction of the automated VMAT planning procedure for NSCLC
treatment at Erasmus MC Cancer Institute has been started in October 2015. A full
speed employment has been scheduled at the beginning of 2016.
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